

## Mixed Models Quantify Annual Volume Change; Linear Regression Determines Thalamic Volume as the Best Subcortical Structure Volume Predictor in Alzheimer's Disease and Aging

Charles S. Leger<sup>1\*</sup>, Monique Herbert<sup>1</sup>, W. Dale Stevens<sup>1</sup>, Joseph F. DeSouza<sup>1</sup>  
for the Alzheimer's Disease Neuroimaging Initiative\*\*

\*Correspondence: Charles S. Leger, Email: [cslfalcon@gmail.com](mailto:cslfalcon@gmail.com)  
<sup>1</sup>York University, Canada

\*\*Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: [http://adni.loni.usc.edu/wp-content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)

1 **Abstract**

2 Background: Thalamus-hippocampus-putamen and thalamus-cerebellar interconnections are  
3 dense. The extent this connectivity is paralleled by each structure's volume impact on another is  
4 unquantified in Alzheimer's disease (AD). Mixed model quantification of annual volume change  
5 in AD is scarce and absent inclusive of the cerebellum, hippocampus, putamen and lateral  
6 ventricles and thalamus. Among these structures, autopsy evidence of early-stage AD seems  
7 largely but not entirely restricted to the hippocampus and thalamus.

8 Objective: Variation in annual volume related to time and baseline age was assessed for the  
9 hippocampus, putamen, cerebellum, lateral ventricles and thalamus. Which subcortical  
10 structure's volume had the largest explanatory effect of volume variation in other subcortical  
11 structures was also determined.

12 Method: The intraclass correlation coefficient was used to assess test-retest reliability of  
13 structure automated segmentation. Linear regression ( $N = 45$ ) determined which structure's  
14 volume most impacted volume of other structures. Finally, mixed models ( $N = 36$ ; 108 data  
15 points) quantified annual structure volume change from baseline to 24-months.

16 Results: High test-retest reliability was indicated by a mean ICC score of .989 ( $SD = .012$ ).  
17 Thalamic volume consistently had the greatest explanatory effect of hippocampal, putamen,  
18 cerebellar and lateral ventricular volume. The group variable proxy for AD significantly  
19 contributed to the best-fitting hippocampal linear regression model, hippocampal and thalamic  
20 longitudinal mixed models, and approached significance in the longitudinal lateral ventricular  
21 mixed model. Mixed models determined time (1 year) had a negative effect on hippocampal,  
22 cerebellar and thalamic volume, no effect on putamen volume, and a positive effect on lateral  
23 ventricular volume. Baseline age had a negative effect on hippocampal and thalamic volume, no  
24 effect on cerebellar or putamen volume and a positive effect on lateral ventricular volume.

25 Interpretation: Linear regression determined thalamic volume as a virtual centralized index of  
26 hippocampal, cerebellar, putamen, and lateral ventricular volume. Relative to linear regression,  
27 longitudinal mixed models had greater sensitivity to detect contribution of early AD, or potential  
28 AD pathology (MCI), via the group variable not just to volume reduction in the hippocampus but  
29 also in the thalamus.

30

31 **Key words: Alzheimer's disease, subcortical volume, linear regression, mixed models**

32

33 Word count: 11,002

34

35

## 36 **Introduction**

37 Hippocampal atrophy, well documented in Alzheimer's Disease (AD) (1, 2), is a  
38 morphological indicator associated with accelerated volume reduction in early AD (3-6).  
39 Hippocampal atrophy is, as might be expected, strongly and positively correlated with  
40 histologically determined (hippocampal) neuron loss (7, 8). Where and when AD pathology  
41 begins remains elusive. Although hippocampal neuron loss and shrinkage undoubtedly  
42 contribute to amnesic dementia in AD (9, 10), AD involves neurodegeneration well beyond the  
43 borders of the hippocampus and other medial temporal lobe structures (11, 12). Moreover,  
44 accumulating evidence, outlined below, strongly suggests AD pathology research should, in  
45 addition to probing status of hippocampal and associated medial temporal lobe structures,  
46 include assessment of thalamic status in particular. Note, unless otherwise stipulated (i.e.,  
47 histological, autopsy data stipulated), volume referred to in the present work is an imaging-based  
48 (mainly MRI) measure.

49 Braak and Braak's seminal autopsy and staging (I-VI progressive stages) of AD revealed  
50 early evidence (stages II-III) of neuropathology in the form of abnormal tau formations (neuritic  
51 threads, plaques and neurofibrillary tangles) particularly in the anterior thalamic nuclei, and  
52 aspects of the entorhinal cortex and hippocampus with lesser such evidence in the striatum and  
53 cerebellum (13, 14). In A-C staging of extracellular amyloid accumulation, substantial amyloid  
54 deposits were revealed at stage C in several thalamic nuclei (anterior, reuniens, etc.) but the  
55 hippocampus had, by comparison, much less neuropathology involvement (14).

56 Thalamic volume is reduced in the potential AD prodrome mild cognitive impairment  
57 (MCI) (15, 16). Thalamic volume is reduced in AD (12, 17, 18), particularly within the medial thalamic

58 nuclei (which includes the anterior, mediodorsal, and reuniens nuclei) <sup>(19)</sup>. In normal aging,  
59 structural alteration of the anterior thalamus is also indicated <sup>(20)</sup>. Annualized volume reduction  
60 of the thalamus has been demonstrated second in extent only to annualized hippocampal volume  
61 reduction <sup>(4)</sup>. Longitudinally, hippocampal atrophy progression/acceleration over 6-12 months  
62 occurs in AD but also in MCI <sup>(6)</sup>. Hippocampal atrophy, particularly in AD but also in normal  
63 aging, is coupled with ventricular enlargement <sup>(12, 21)</sup>.

64         There are inconsistent findings for altered putamen volume in AD. Putamen volume has  
65 been reported as unaltered in AD <sup>(22)</sup> as well as reduced in AD <sup>(4, 17)</sup>. The cerebellum, implicated  
66 in cognitive AD dysfunction <sup>(23)</sup>, has also demonstrated mixed volumetric findings in AD.  
67 Cerebellar atrophy seems largely spared in AD <sup>(24)</sup> but has been reported as both greater than in  
68 normal aging <sup>(25, 26)</sup>, and similar to that in normal aging in cross-sectional and longitudinal  
69 analyses <sup>(27)</sup>.

70         Volume of any structure is integrated with a physiological system that includes  
71 connectivity. Thalamic connectivity, particularly diverse, has bidirectional or looping circuits  
72 involving cortical regions, basal ganglia, and limbic (e.g., hippocampus, posterior cingulate  
73 cortex, fornix, piriform cortex, amygdala) structures <sup>(11, 28)</sup>. There is also a plethora of reciprocal  
74 cerebellar-thalamic connections <sup>(29-32)</sup>. Recent diffusion-weighted imaging, incorporating a large  
75 data sample ( $N = 730$ ), has substantiated the elaborate and dense fiber pathways interconnecting  
76 the thalamic anterior nuclei and the hippocampus as well as other limbic system structures <sup>(33)</sup>.  
77 Moreover, as concluded in meta-analytic research involving over ten-thousand human brain  
78 imaging studies, focal lesions of the thalamus have widespread repercussions, disrupting diverse  
79 cortical functional networks, further exemplifying the hub-like role of the thalamus <sup>(34)</sup>. In short,

80 the thalamus is diversely interconnected with other structures; dysfunction in the thalamus, or in  
81 one or more of its subdivisions, has demonstrated impact extending outside thalamic borders [\(35\)](#).  
82 [\(36\)](#).

83 The current work used normalized volume in early AD, potential AD (MCI) and controls  
84 (CN) of five structures: cerebellum, hippocampus, putamen, lateral ventricles and thalamus.  
85 These structures, as reviewed, can be impacted by AD or normal aging. Separate linear and  
86 longitudinal mixed model regression analyses assessed volume of the structures. Notable, three  
87 of the structures (cerebellum, hippocampus, putamen), as reviewed, are densely interconnected  
88 with the thalamus, or with respect to the lateral ventricles anatomically juxtaposed to the  
89 thalamus. Further, early stage AD-type pathology (abnormal tau formations) is localized largely,  
90 though not entirely, to the hippocampus and thalamus [\(13, 14\)](#). In short, thalamic connectivity [\(34\)](#),  
91 thalamic early-stage AD involvement [\(13, 14\)](#) and volume change [\(12, 18, 19, 37\)](#) combine to suggest the  
92 potential of this single structure to inform on the status of the other four structures (cerebellum,  
93 hippocampus, putamen, lateral ventricles) in early AD. As already noted, (normalized) volume  
94 was the metric of interest. Volume served as the response variable (univariate) in five distinct  
95 linear and five distinct mixed models. Explanatory variables were selected from the literature and  
96 refined in regression procedures. Linear regression explanatory variables were initially baseline  
97 age, gender, cognitive measures, the group variable (AD, MCI, CN) as well as the volume of the  
98 other structures. The AD and MCI groups, as defined by the Alzheimer's Disease Neuroimaging  
99 Initiative [\(45\)](#), represented early AD and potential AD (MCI); the group variable AD and MCI  
100 cohorts, served as a proxy for early AD or MCI. In linear regression models, each structure's  
101 volume served as a response variable once and as an explanatory variable four times (given five  
102 structures other than the response variable). This, model-based approach, assessed contribution

103 of a given predictor, including another structure's volume, to predict/explain volume of the  
104 response variable structure volume. Mixed model explanatory variables were effects of time,  
105 baseline age and group. As with linear regression, each structure's volume model determined  
106 explanatory variables contributing most to volume. Evidence of early stage hippocampus and  
107 thalamus (13, 14) AD-type pathology prompted the first avenue of inquiry: does the presence of  
108 early-stage hippocampal and thalamic AD pathology account for greater AD-related variation in  
109 hippocampal and thalamic volume compared to AD-related volume variation in the other three  
110 structures? Indication of early-stage AD pathology particularly in the thalamus and hippocampus  
111 (13, 14) coupled with the dense interconnections among these structures (33, 38-40) implies a possibly  
112 linked hippocampus-thalamus neuronal fate in early-stage AD. As such, significant explanatory  
113 effects/estimates of the group variable AD and MCI cohorts were expected for thalamic and  
114 hippocampal volume regression models (linear and mixed). In a second vein of inquiry, linear  
115 regression determined if any single structure's volume as an explanatory variable accounted  
116 consistently for more variation in response structure volume. It was expected that thalamic  
117 volume as an explanatory variable would parallel the central and impactful effect of thalamic  
118 connectivity (briefly outlined in the preceding paragraph) in normal aging and early AD. To the  
119 best of our knowledge, study objectives and methods (see Materials and methods) are unique  
120 within the context of early AD investigation.

## 121 2. Materials and methods

### 122 *Procedures and power analyses*

123 The main measure of interest was, the biological indicator, MRI-based subcortical  
124 structure volume of the hippocampus, cerebellum, putamen, hippocampus and thalamus.

125 Subcortical structure segmentation/volume estimates were completed using the dedicated  
126 volumetry platform volBrain <sup>(41)</sup> (<https://volbrain.upv.es>). As outlined in the preceding statement,  
127 regression models (univariate) were the principal method of assessment. Prior to regression  
128 analyses test-retest reliability of volBrain <sup>(42)</sup> subcortical segmentation was determined using the  
129 intraclass correlation coefficient (ICC). Prior to the mixed model analysis a repeated-measures  
130 correlation <sup>(43)</sup> analysis was conducted. Finally, subsequent to mixed model analyses, a simple  
131 annualized volume calculation was completed (see Supporting information II for details).

132         Linear and mixed model power analyses were conducted to estimate the minimum  
133 number of data instances required to provide at least 80% power to reject the null hypothesis  
134 with an appropriate effect size. An initial power analysis for the linear multiple regression  
135 models indicated a model with 2 to 3 predictors, a large .80 effect size and 80% power at  $\alpha = .05$   
136 would require  $N = 45$  subjects (at least 13 per group, where analyses included 3 groups).  
137 Accordingly, the preference was to obtain a baseline study sample of at least 45, with 15 unique  
138 records per group (AD, CN, MCI). The actual power achieved in the linear model results ranged  
139 from a low .85% with an adjusted  $R^2$  of .25 to a high for the hippocampus and thalamic models  
140 of .99% and an adjusted  $R^2$  of between .52 and .67.

141         With respect to a longitudinal mixed model power analysis, some loss of records was  
142 expected across time. As such, we ran some preliminary mixed model simulations <sup>(44)</sup> with an  $n =$   
143 30 (unique records) across 3 time points (90 data instances), one fixed effect, time, and the  
144 subject intercept random effect. Simulations with a conservative effect size of -0.07 using the full  
145 90 data instances had a power of 92.50%. The actual longitudinal data set proved to have a range  
146 of 33-36 unique complete cases of data (99-108 data instances over 3 time points), fixed effects

147 estimates ranged from -.13 for the hippocampal model AD group dummy variable to nil for the  
148 putamen model. Actual mixed model pseudo  $R^2$  ( $pR^2m = \text{fixed effects}$ ,  $pR^2c = \text{fixed plus random}$   
149  $\text{effects}$ ) ranged from  $pR^2m$  .53 and  $pR^2c$  .99 in the hippocampal model to nil  $pR^2m$  and  $pR^2c$  .97  
150 in the putamen model.

## 151 2.2 Subject data

152 Data was sourced from the Alzheimer's Disease Neuroimaging Initiative <sup>(45)</sup> (ADNI) database.  
153 Specifically, ANDI 1 and ADNI GO data was used. ADNI is a public-private partnership  
154 initiated in 2003, and led by principal investigator Michal W. Weiner MD. The main objective of  
155 ADNI has been to investigate whether serial magnetic resonance imaging (MRI), positron  
156 emission tomography (PET), other markers (biologics, clinical and neuropsychological  
157 assessments) can be combined to quantify progression of early Alzheimer's disease (AD) and  
158 mild cognitive impairment (MCI). Up to-date information can be found at [www.adni-info.org](http://www.adni-info.org).

159 ADNI's unique back-to-back (BTB) baseline and 12-month same-subject scan pairs were  
160 used to assess subject intra-session scan segmentation test-retest reliability (see 2.5). These BTB  
161 scans are same-subject T1 images taken minutes apart resulting in baseline and month twelve  
162 pairs of scans per subject. Using ADNI's online image Advanced Search interface, the following  
163 criteria were used: original, pre-processed and processed data; ADNI 1, ADNIGO; AD, CN MCI  
164 cohorts, present at baseline and 12 months; age range 55-88; MMSE and CDR included; 3T; T1.  
165 This returned 3311 scans of which 156 scans represented distinct, individual subject data. During  
166 inspection of scans, artifacts were most common in those subjects who had multiple repeats of  
167 scans at baseline and at 12-month time points. After filtering-out those subjects with greater than  
168 10 scans per time point, the pool of subjects was reduced to 72. After a final and closer



169 inspection of these scans, 47 were selected. Of these, volBrain processing errors occurred for two  
170 MCI cohort members (023\_S\_1126 and 023\_S\_1247). This left an intra-session dataset for test-  
171 retest reliability (see section 2.5) involving 180 scans from 45 subjects (15 per AD, CN and MCI  
172 groups times 4 BTB intra-session scan pairs).

173         Linear regression analyses (see section 2.5) used baseline scans and data from 45  
174 subjects: 15 AD, 12 female; 15 healthy age-matched CN, 7 female; and 15 scans from the MCI  
175 group, 5 female. The AD cohort was relatively early stage, pre-dementia or mild dementia based  
176 on ADNI classification.

177         With regard to the longitudinal mixed model dataset, nine cases present in the original  
178 baseline ( $n = 45$ ) and 12-month data were absent in the 24-month data. This resulted in a final  
179 longitudinal 36-subject dataset with complete case data at all three time points: 10 AD, 14 CN,  
180 and 12 MCI at each of the baseline, 12-month and 24-month timepoints. It is acknowledged  
181 mixed model intercepts could have benefited by utilizing all 45 cases with available data at  
182 baseline and 12-months. Nevertheless, in this analysis, only complete cases, the 36 cases present  
183 at all time points, were to be used in the longitudinal mixed model analyses. Further, from this  
184 group of 36 complete cases, the final longitudinal data set had a final range of 33-36 unique  
185 complete cases of data (99-108 data instances over 3 time points). With the exception of the  
186 lateral ventricular mixed model, 1 to 3 data instances in mixed models proved overly influential.  
187 These cases were removed. See *Supporting information VI* for Mixed model diagnostics details.

188         Clinical and demographic data were utilized in regression analyses that followed  
189 volBrain intra-session segmentation test-retest reliability assessment. Cognitive measures were  
190 the Mini-Mental State Examination (MMSE: maximum score of 30 higher is better) <sup>(46)</sup>, and the

191 Clinical Dementia Rating <sup>(47, 48)</sup> scale (CDR: normal = 0, and .5, 1, 2, and 3 respectively reflect  
192 very mild, mild, moderate and severe dementia). The demographic variables were age and  
193 gender. However, notable, among the explanatory variables included in models initially, gender  
194 did not make a significant contribution to any model. In addition, there was a large imbalance in  
195 gender, especially for the AD group. To avoid misleading regression estimates gender was not  
196 included in models.

### 197 2.3 *MRI acquisition*

198 Acquisition of ADNI MPRAGE pulse sequences was highly standardized <sup>(49)</sup> across  
199 multiple sites utilizing GE, Philips or Siemens equipment: baseline, month-12, and 24-month  
200 same-subject scans employed the same sequences at 3T. MPRAGE T1 preprocessing was  
201 restricted to conversion from DICOM to NIFTI format. The slice thickness for these samples  
202 was consistently 1.2 mm and all pixels were square. Voxel volume range was 1.20 mm<sup>3</sup> to 1.24  
203 mm<sup>3</sup>. All images were carefully inspected for artefacts.

### 204 2.4 *Automated segmentation*

205 VolBrain <sup>(42)</sup> is an online platform (<http://volbrain.upv.es>) dedicated to volumetric analyses. A  
206 so-called patch-based method, it has a fully automated pipeline based on fusion of multiple  
207 atlases <sup>(41, 42)</sup>. We used the default volBrain library, which consists of 50 T1-weighted images  
208 (MPRAGE and SPGR). The volBrain pipeline consists of several steps: denoising,  
209 inhomogeneity correction, registration of affine to MNI space, fine inhomogeneity correction,  
210 intensity normalization, intracranial cavity extraction, tissue classification, non-local hemisphere  
211 segmentation, and subcortical non-local segmentation.

## 212 2.5 *Statistical analyses*

213 As outlined in section 2.2, two baseline ( $V_{0A}$  and  $V_{0B}$ ) and two 12-month ( $V_{12A}$  and  
214  $V_{12B}$ ) same-subject scan pairs were used to assess test-retest reliability of these intra-session  
215 scans. Segmentation test-retest reliability was assessed with the intraclass correlation coefficient  
216 (ICC) for agreement using same-subject (intra-session) baseline and 12-month scan pairs. ICC  
217 was used to assess agreement between baseline (same subject) scan pairs  $V_{0A}$  and  $V_{0B}$  and then  
218 between  $V_{12A}$  and  $V_{12B}$  scan pairs. The ICC was calculated by group for both left and right  
219 hemisphere using raw structure volume.

220 Regression analysis were conducted using normalized volume of the hippocampus,  
221 putamen, thalamus, lateral ventricles and the cerebellum. Normalized volume was a relative  
222 measure: a ratio of structure total (left plus the right) volume to total intracranial volume (ICV).  
223 Normalized volume values are a percent: e.g., structure volume/ICV \* 100. The type I error rate  
224 for regression analyses was set at .05 ( $\alpha = .05$ ). As always, regression coefficients quantify the  
225 magnitude or strength of the predictor/explanatory/independent variable effect on outcome. The  
226 extent of any explanatory variable effect, the extent that it explains variation in outcome, should  
227 not be confused with mediation in this research – this research uses regression not mediation.

### 228 2.5.1 *Linear regression methods*

229 Each structure's volume served as a response variable once and as an explanatory variable four  
230 times (given five structures). Having each structure serve once as the response variable but  
231 otherwise in an explanatory variable role allowed for structure/model-based determination of  
232 which structure's volume most effected volume of other structures. Along with volumes of  
233 structures, linear regression explanatory variables were baseline age, cognitive measures

234 (MMSE, CDR) and the group variable, where AD and MCI cohorts, served as a proxy for early  
235 AD or MCI. Owing to the gross imbalance in cell size with respect to gender (e.g., the baseline  
236 AD group had 12 females but just 3 males; and the 24-month data AD data had 9 females but  
237 just one male, see 2.1), and to avoid a misleading outcome, gender was not used as a covariate.  
238 Stepwise regression (backward, using AIC) was used to aid in selection optimal final model  
239 features. All final linear regression models complied with regression assumptions and there was  
240 an absence of overly influential observations. It warrants note however that the group and  
241 clinical dementia rating (CDR) explanatory variables were too highly correlated ( $r_s = .87$ ) to  
242 include in the same model, hence these two variables were examined in two distinct regression  
243 analyses. Only models with hippocampal volume as the response variable retained the CDR and  
244 group variables. Two linear regression hippocampal models were conducted: one using the group  
245 variable and one using CDR. For each linear model, 2-way interactions were assessed for  
246 explanatory volume variables by age and explanatory volume variables by group in final models  
247 retaining the variables. It warrants note that each of the five structures has as a differing volume  
248 range or scale of values, making direct comparison among structure RMSE values inappropriate.  
249 To aid in comparison, a normalized version of RMSE, NRMSE, was also calculated: the  
250 NRMSE was approximated by dividing the RMSE by the standard deviation of Y. Standardized  
251 estimates/coefficients, also provided, are unitless and therefore facilitate comparisons of  
252 differently scaled variables<sup>(50)</sup>. The principal of parsimony was adhered to for both linear  
253 regression and mixed linear regression models: if the addition of an explanatory variable did not  
254 significantly improve the fit of the model to the data, the term was dropped and the simpler  
255 model retained.

## 256 2.5.2 Linear mixed model methods

257 In mixed longitudinal models, the response variable was, as in linear regression, the volume of a  
258 single structure. Mixed models focused on quantifying explanatory variable contribution  
259 (notably the group variable AD and MCI cohorts that served as proxies for early AD or MCI.) to  
260 annual volume change in the same five structures over two years. The mixed model explanatory  
261 variables were effects of time, baseline age and group. Prior to conducting mixed model analysis,  
262 a repeated-measures correlation analysis was conducted to assess the nature of bivariate  
263 relationships between variables. The software package used <sup>(43)</sup> calculates a repeated-measures  
264 coefficient ( $r_{rm}$ ) that has a -1 to 1 index of association strength between two variables analogous  
265 to Pearson  $r$ , but unlike the latter does not violate the assumption of observation independence;  
266 non-independence is accounted for. The  $r_{rm}$  provides quick longitudinal insight. Compared to a  
267 mixed model, however, there are two main limitations. First, as with Pearson correlation, only  
268 the relationship between two variables can be assessed simultaneously. Second, it is analogous to  
269 the mixed null model, including only the random (varying) subject intercept (mean) and the  
270 overall slope (intercept) <sup>(43)</sup>.

271 The linear mixed algorithm models account for dependence (non-independence of  
272 residuals) by including random, individual subject idiosyncratic variability in mean volume (the  
273 intercept) as well as subject variability in the effect of time on volume. The mixed longitudinal  
274 volume analyses, as with the linear regression analyses, involved separate analysis for  
275 hippocampal, putamen, thalamus, cerebellum and lateral ventricular volume. Also similar to the  
276 linear model procedures, the mixed model response variable was normalized volume of one of  
277 the latter structures. However, unlike the procedure for the linear models, volumes of the  
278 structures other than the response variable did not serve as explanatory variables. The mixed  
279 model fixed effect explanatory variables were time (baseline, 12-month, and 24-month time

280 points) baseline age and group. Time was included as a numeric variable, an approach adopted in  
281 a much-cited paper [\(51\)](#). Age and time points will covary when time and age are included in a  
282 longitudinal analysis. To control time-age collinearity, static baseline age was used. Baseline age  
283 and time (for all 3 time points) were centered to assess interactions. A time by group (AD, CN,  
284 MCI) interaction was examined for each model. Random effects consisted of individual subject  
285 intercept and the individual subject slope of time.

286 As in the linear regression models, in the mixed model analysis volume of one of five  
287 subcortical structures (the hippocampus, cerebellum, putamen, lateral ventricles or thalamus)  
288 served as the response variable in separate models. Mixed model independent (fixed effect) main  
289 effect variables consisted of baseline age, time and group.

290 Separate mixed models were executed in the recommended sequence [\(52-53\)](#). Specifically,  
291 mixed models began with the simplest model and progressed in complexity. Seven different  
292 levels of complexity (i.e., model types 1 to 7, see below), were executed using the total  
293 normalized volume of each structure as the response variable. Only the final model with the best,  
294 most parsimonious fit to the data was reported in detail. However, a comparison of all model  
295 type results is provided in *Supporting information I*. Again, for each of the five structures, seven  
296 different model types were executed with 1-7 levels of complexity. Initially, an intercept only  
297 (unconditional) model was assessed, a model where the intercept did not vary (volume was  
298 simply regressed on the constant 1). This unconditional model was executed using generalized  
299 least squares (model 1). Next, another unconditional model was executed in which intercepts  
300 were random, permitting means to vary across subjects (model 2). This adds to the overall model  
301 intercept the effect of subject-specific intercepts. This accounts for structure volume nested

302 within subjects (individual variation in volume). In model 3, time was added as a random effect  
303 of subject. The random slope of time for each subject assessed the extent the effect of time on  
304 volume differs for each subject. Again, bear in mind, that longitudinally, the effect of time is  
305 nested within subjects. Next, in model 4, time was added as a fixed effect, which as in standard  
306 linear regression, estimates, on average, the effect of time on volume across all individuals. The  
307 next level of model complexity, model 5, added the fixed effect of baseline age. The model 6  
308 added the effect of group (AD, CN, MCI) to determine the effect of group membership on  
309 volume; AD vs controls (the reference group) and MCI vs controls. Finally, a model 7 was added  
310 that involved a group by time interaction. In addition, a quadratic fixed effect time variable was  
311 also included to assess potential quadratic, accelerated, effect of time (i.e.,  $\text{time}^2$ ) in the model.  
312 Adding a random quadratic term for time to the random effects of time and subject is optional; a  
313 quadratic effect of time can be included as a fixed only or as both a fixed and random effect (52).  
314 In general, whether it necessary to include all fixed effects also as random effects is a subject of  
315 debate that can be reviewed various statistics forums.

316 Measures of model fit, for a given structure's longitudinal volume assessment, used to  
317 compare across model types (1 to 7 as described above), were Akaike Information criterion  
318 (AIC), deviance (or loglikelihood) and chi-squared statistic (or a likelihood ratio test), RMSE  
319 and NRMSE and pseudo  $R^2$  (54). The latter pseudo  $R^2$  has two components:  $pR^2_m$ , which refers to  
320 the fixed effects (marginal) contribution and  $pR^2_c$ , which refers to total fixed plus the random  
321 effects contribution to pseudo variance accounted for by the model. The chi-squared statistic was  
322 used for model type (1 to 7) comparison. To facilitate comparison of models the maximum  
323 likelihood (ML) method of estimating mixed model parameters was used, though it is recognized  
324 that restricted maximum likelihood (REML) has demonstrated more precise and less biased

325 random effect variance component estimates <sup>(55)</sup>. Also, formal pairwise tests, where appropriate,  
326 were conducted on final models using a Tukey test. In addition, a standard Cohen's *D* effect size  
327 was adopted to assess pairwise test effect size. The standard Cohen's *D* ignores design (between-  
328 subject, mixed model etc.) information. While mixed-model specific effect sizes methods can be  
329 adopted it has been convincingly argued that such tests impair comparison of effects across  
330 differing analysis designs <sup>(56)</sup>.


### 331 *2.5.3 Regression model diagnostics*

332 To mitigate against overfitting, all linear and mixed regression models were compliant  
333 with a relaxed one predictor to five event (data instance) rule of thumb <sup>(57)</sup>. Four of the linear  
334 regression models complied with the more stringent one predictor to ten events rule of thumb <sup>(58)</sup>,  
335 and three of five mixed models complied with one predictor to ten events rule of thumb (see  
336 *Supporting information VI* for mixed model diagnostic details). All model residuals were  
337 assessed for regression assumption violation (including mixed model random effects) and the  
338 presence of influential cases. Note, two mixed model packages were used, package *lme4* <sup>(51)</sup>;  
339 package *nlme* <sup>(59)</sup>. This served as a check on analyses and also offered some methodological  
340 latitude. Analyses were conducted in *R* <sup>(60)</sup> on a 4-core, (3.2 GHz, 6 GB) Apple OS Higher  
341 Sierra (v. 10.13.6) system.

## 342 **3.0 Results**

343





344

345 **FIG 1** Subcortical structure mapping in MNI 152 space (.5mm). (A) Three cardinal planes MNI -3.93, -13.61, 9.29; x=94, y = 112, z= 81; (B)  
 346 color coded legend; (C) VolBrain Subcortical parcellation in MNI 152 space. AD = Alzheimer's disease; MCI = mild cognitive impairment; CN  
 347 = controls CB = cerebellum (dark brown); HPC=hippocampus (Copper); PUT = putamen(yellow); LV = lateral ventricles (purple); THAL =  
 348 thalamus (turquoise; surrounded by white boarder in A). Structures in A derived from Harvard-Oxford Subcortical Structural Atlas. Anterior  
 349 thalamic nuclei group (red) and the lateral dorsal thalamic nucleus (red) (Krauth et al., 2010). Note, the lateral dorsal nucleus is often included  
 350 as part of the anterior thalamic nuclei group. Radiological convention using FSLeyes version 1.3.0.  
 351

352 FIG 1 (A) depicts the subcortical structures of interest in MNI 152 space. FIG 1 (B) displays the  
 353 color coding for structures. Notable, only volumetry of whole structures was used. However, FIG  
 354 1 (A) also localizes thalamic anterior nuclei (red segments on the anterior/superior aspect of the

355 turquoise-colored thalamus in FIG 1 A). The anterior thalamic nuclei group are localized in FIG  
356 1 (A) because they were referred to in the introduction and will be included in the next phase of  
357 this project. VolBrain parcellation is provided in FIG 1 (C). The volBrain parcellation in FIG 1  
358 (C) includes, by default, other structures not assessed in the current work. Only structures  
359 matching the color coding in (B) are relevant.

360 **Table 1** contains baseline demographic, MMSE, CDR, as well as raw, non-normalized,  
361 volume measures in mm<sup>3</sup>. Measures are arranged by group (AD, MCI, CN). The volBrain  
362 volume estimates are consistent with other AD research <sup>(61)</sup> where cohorts were of similar age as  
363 those in the current work.

364 Intraclass correlation coefficient (ICC), test-retest reliability was high as indicated by the  
365 mean ICC score of .989 ( $SD = .012$ ). The lowest ICC was .937 (95% CI .829, .978) for the 12-  
366 month time-point measure of the left hippocampal hemisphere in controls. For details on all ICC  
367 measures see Table S1-11 in *Supporting Information I*.

368 Group measures of baseline age, gender MMSE, and CDR were initially assessed.  
369 Binomial tests within AD, controls and MCI groups indicated AD cohort gender imbalance; a  
370 proportion of .80 females (12/15 = .80 female), which significantly differed from the expected  
371 proportion of .5 (50%),  $p = .035$  (95% CI .52, .96). Because of this gender imbalance, noted  
372 earlier, and its potential to bias models, gender was not included as a variable. ANOVA indicated  
373 age (which did not violate homogeneity of variance across groups) did not significantly differ  
374 among groups,  $F(2,42) = .87$ ,  $p = .26$ . Kruskal-Wallis tests were used to test MMSE and CDR.  
375 Each of the latter two variables had non-normal distributions and high heteroscedasticity. MMSE  
376 scores did significantly differ among groups,  $\chi^2(2) = 26.9$ ,  $p < .0001$ ,  $r^2_{adj} = .59$  ( $r^2_{adj}$  ANOVA

377 on ranks). A posthoc Dunn Test, controlling for multiple comparisons (Benjamin-Hochberg),  
 378 indicated AD ( $p < .0001$ ) and MCI ( $p < .001$ ) groups significantly differed from controls. The  
 379 MMSE mean scores of AD and MCI cohorts did not significantly differ,  $p = .30$ . The pattern was  
 380 the same for CDR scores. CDR mean scores significantly differed among groups,  $\chi^2 (2) = 35.2$ ,  $p$   
 381  $< .0001$ ,  $r^2_{adj} = .79$ . A post hoc Dunn's Test, controlling for multiple comparisons (Benjamin-  
 382 Hochberg), indicated AD and MCI groups significantly differed from controls ( $p < .0001$ ). The  
 383 CDR mean scores of AD and MCI cohorts did not significantly differ,  $p = .09$ .

**TABLE 1: Demographics, MMSE, CDR, baseline volume,  $N=45$**

	AD ( $n = 15$ )	CN ( $n = 15$ )	MCI ( $n = 15$ )
<i>Measures</i>	<i>Mean (SD)</i>	<i>Mean (SD)</i>	<i>Mean (SD)</i>
Age	74 (8)	74 (8)	73 (8)
CDR (median, range)	.5 (.5, 1)	0 (0, .5)	.5 (.5, .5)
MMSE	22 (5)	29 (1)	25 (3)
<i>Baseline volume mm<sup>3</sup></i>	<i>Mean (SD)</i>	<i>Mean (SD)</i>	<i>Mean (SD)</i>
CB	59267 (10454)	61901 (4202)	64346 (9631)
HIPP	2942 (635)	3783 (485)	3216 (549)
LV	20532 (16096)	14179 (7031)	23840 (12776)
PUT	3971 (669)	3980 (413)	3914 (508)
THAL	4811 (620)	5094 (590)	5025 (472)

384 AD = Alzheimer's disease; MCI = mild cognitive impairment; CN =  
 385 controls; CDR = cognitive dementia rating: 0 – 5, 0 is normal; MMSE = Mini-  
 386 Mental State Examination: maximum of 30 points, 25- 30 normal cognition,  
 387 21-24 mild dementia, 10-20 moderate dementia,  $\leq 9$  severe dementia); THAL  
 388 = thalamus; HIPP = hippocampus; PUT = putamen; volumes are baseline  
 389 structure averages across hemispheres in mm<sup>3</sup>, e.g., left CB + right CB)/ 2;  
 390 values are mean and SD unless otherwise indicated. All volume measures  
 391 in this table are in native space.  
 392

### 393 3.1 Normalized volume by group

394 All structure volume measures used in the regression analyses were normalized, where  
 395 normalized refers to a given structure's volume relative to total intracranial volume (ICV);  
 396 values are percentages – i.e., structure volume/ICV \* 100. **Table 2** specifies volBrain normalized  
 397 structure volume for the baseline dataset used in the linear regression analyses ( $N= 45$ : AD= 15,

398 CN=15, MCI =15) and for the longitudinal 36-subject dataset (AD = 10, CN = 14, MC =12) used  
 399 in mixed model analyses. The longitudinal 36-subject dataset had complete data instances across  
 400 baseline, 12-month, and 24-month time-points. Again, structure volume is provided as a  
 401 percentage of total intracranial volume. The median longitudinal volume values tabulated in  
 402 **Table 2** convey apparent small reductions in hippocampal and thalamic volume across groups,  
 403 with less discernable 24-month change in putamen and cerebellar volume. Also indicated in the  
 404 longitudinal data, the lateral ventricles had a pattern of increasing size over 24 months.


**TABLE 2: Normalized structure volume as a percentage of total intracranial volume; median and range**

	<i>HPC</i>	<i>PUT</i>	<i>THAL</i>	<i>LAT VENT</i>	<i>CB</i>	<i>AGE</i>	<i>CDR</i>	<i>MMSE</i>
	<i>MDN (rng)</i>	<i>MDN (rng)</i>	<i>MDN (rng)</i>	<i>MDN (rng)</i>	<i>MDN (rng)</i>	<i>MDN (rng)</i>	<i>MDN (rng)</i>	<i>MDN (rng)</i>
<b>Gp Time</b>								
<b><u>Baseline data, N = 45: 15 AD, 15 CN, 15 MCI</u></b>								
AD base	.42 (.29, .58)	.59 (.50, .70)	.72 (.56, .84)	2.42 (.96, 8)	8.86 (6.67, 10)	72 (57,86)	.5 (.5, 1)	24 (13, 29)
CN base	.56 (.41, .67)	.58 (.51, .64)	.79 (.60, .84)	1.68 (.68, 4)	8.96 (7.74, 10.6)	73 (60, 86)	0 (0, .5)	30 (27, 30)
MCI base	.43 (.34, .59)	.55 (.41, .63)	.69 (.59, .81)	3.05 (1, 5.5)	8.63 (7.02, 11)	73 (56,88)	.5 (.5, .5)	26 (19, 29)
<b><u>Longitudinal (3 time-points): AD n = 30 (10 x 3), CN n = 42 (14 x 3), MCI n = 36 (12 x 3)</u></b>								
AD base	.41 (.29, .57)	.59 (.50, .69)	.70 (.56, .82)	2.7 7(.96, 5.6)	8.91 (6.7, 10)	72 (64, 85)	1 (.5, 2)	24 (13, 29)
AD m12	.38 (.27, .57)	.58 (.49, .69)	.70 (.58, .81)	3.25 (.87, 6.13)	8.8 (6.8,9.9)	73 (65, 86)	1 (.5, 2)	24 (13, 29)
AD m24	.36 (.25, .56)	.56 (.47, .68)	.68 (.56, .80)	3.73 (1.2, 7.93)	8.7 (6.7, 9.9)	74 (66, 87)	1 (.5, 2)	22 (10, 27)
CN base	.55 (.41, .62)	.58 (.51, .64)	.79 (.60, .84)	1.67 (.68, 3.72)	8.9 (8,10)	73 (60, 86)	0 (0, .5)	30 (27, 30)
CN m12	.55 (.42, .62)	.57 (.50, .64)	.75 (.61, .82)	1.98 (.70, 3.73)	8.8 (7.9, 10.5)	74 (61, 87)	0 (0, .5)	30 (27,30)
CN m24	.52 (.41, .61)	.57 (.52, .66)	.72 (.59, .83)	2.28 (.75, 3.98)	8.9 (7.8, 10.6)	75 (62, 88)	0 (0, .5)	30 (27, 30)
MCI base	.45 (.34, .59)	.56 (.47, .63)	.69 (.59, .81)	2.56 (1.0, 5.51)	8.88 (7.02, 10.8)	72 (56, 83)	.5 (.5, .5)	26 (19, 29)
MCI m12	.44 (.35, .57)	.56 (.46, .65)	.68 (.58, .81)	2.96 (1.21, 5.61)	8.91 (7.2, 10.7)	73 (57, 84)	.5 (.5, .5)	26 (19, 29)
MCI m24	.44 (.34, .57)	.56 (.46, .67)	.66 (.59, .81)	3.19 (1.31, 6.33)	8.9 (7.4, 10.5)	74 (58, 85)	.5 (.5, 1)	25 (11,30)

405 *AD = Alzheimer's disease group; CN = controls; MCI = mild cognitively impaired CB = cerebellum; HPC= hippocampus; PUT = putamen; LAT*  
 406 *VENT = lateral ventricles Gp = group; base = baseline; m12 = 12 months post baseline; m24 = 24 months post baseline; MDN = median; rng=*  
 407 *range; Structure volume is a percentage of total intracranial normalized volume: e.g., for the median AD longitudinal baseline hippocampus*  
 408 *volume, left + right hippocampal volume / total intracranial volume \*100 = .41.*  
 409  
 410

411 FIG 2 provides additional insight into volume change between time points (baseline vs.  
412 12-months; baseline vs 24-months; 12-months vs. 24-months) within groups. Structure volumes  
413 in FIG 2 reflect normalized volume (e.g., left + right hippocampal volume / total intracranial  
414 volume \*100), Normalized structure volume was converted to a z-score to facilitate across  
415 structure comparison. FIG 2 panels reflect hippocampal (A), lateral ventricular (B) and thalamic  
416 (C) volume between time point tests (baseline, 12-months and 24-months) for each group. False  
417 discovery rate was used to adjust p-value values for multiple comparisons. Plot values (x-axes)  
418 are in standard deviations. The same volume pairwise tests between time points for cerebellar  
419 and putamen volume is provided in Table S1-24 (see Supporting information I). Table S1-24 will  
420 indicate significant ( $p < .05$ ) putamen volume changes only for the AD cohort between each time  
421 point but no significant cerebellar volume differences between time points for all groups.

### Between time point volume comparisons within groups



422  
423  
424  
425  
426  
427  
428  
429  
430

**FIG 2 Between time-point comparisons.** AD = Alzheimer's, CN = controls, MCI = mild cognitively impaired. X-axes in panels X-axes reflect the standard deviation (mean = 0) of normalized volume (e.g., left + right hemisphere volume / total intracranial volume \*100); y-axis indicates group; time is color coded. Panels A, B and C are the respective hippocampal (HPC), thalamus (THAL) and lateral ventricular (LV) normalized volumes as z-scores; \* =  $p < .05$ ; \*\* =  $p < .01$ ; \*\*\* =  $p < .001$ . Note, the non-normality of lateral ventricular volume required robust (Wilcox) pairwise tests. Plots based on longitudinal baseline, 12-month and 24-month data.

431 *4.1 Linear regression volume analyses*

432 Linear regression analyses were conducted using baseline data. This dataset had 45  
433 subjects, 15 in each group. See section *2.5.1 Linear regression methods* for more method  
434 information (additional details are available in *Supporting Information IV*). The main objective  
435 was to determine the combination of variables (structure volume, age, group, and MMSE) that  
436 best explained a given structure's volume (see section *2.5.1 Linear regression methods*). Results  
437 of all the final (best fitting) models) are detailed in **Table 3**. Tabulated values reflect the effect of  
438 a given predictor on the outcome measure (fractional measure: structure volume / total  
439 intracranial volume \* 100). Only the models mitigating against overfitting with the best data fit  
440 (based on criteria including model RMSE, *adjusted-R<sup>2</sup>*, and variable estimates) are reported in  
441 **Table 3**. The thalamus (normalized volume), as an explanatory variable (i.e., that  
442 explains/predicts outcome), had the largest significant estimate in all models. Model predicted  
443 means were as follows: cerebellar volume 8.83% (95% CI 8.61, 9.05); putamen volume, .573%  
444 (95% CI .56, .59); lateral ventricles, 2.35% (95% CI 2.12, 2.60); thalamus, .727, (95% CI .71,  
445 .74). A range of model volume predicted values (e.g., using first and third quarter predictor data  
446 values) is available on request.

447 A non-linear relation found initially in the lateral ventricular model was corrected by log  
448 transform of the dependent and independent variables. All final models complied with  
449 assumptions as tested using a comprehensive test <sup>(63)</sup> and plots (see *Supporting information I*, S1-  
450 2 to S1-12). There were no overly influential cases as measured by Cook's distance (4/n).

451 Two thalamic volume models were retained because one of them (THAL mod 2, see  
452 **Table 3**), included an interaction term. This precluded compliance with the ten (data instances)

453 to one predictor rule of thumb <sup>(58)</sup>, a guideline to mitigate against overfitting. The THAL mod 2,  
 454 while not complying with this rule of thumb, provides some insight into a hippocampal volume  
 455 by age interaction that could occur in a larger data set. Moreover, the THAL mod 2 did comply  
 456 with the less a stringent one predictor to five data instance rule of thumb <sup>(57)</sup>. In addition, as a  
 457 further check against overfitting, a predictive R-squared calculation was applied to THAL mod  
 458 2. There was only a small discrepancy between the THAL mod 2 adjusted  $R^2$ .67 and the  
 459 predictive  $R^2$  outcome of .62, suggesting that this model was not overfitted. Nevertheless, a  
 460 thalamic model compliant with the traditional ten to one rule of thumb (THAL mod 1, **Table 3**)  
 461 was also retained.

462 In the hippocampal volume model HPC mod 1, stepwise regression (backward, using  
 463 AIC), used to help narrow the final set of all model predictors, originally retained the  
 464 explanatory variable cerebellar (CB) volume. The CB predictor was not retained as it made  
 465 negligible difference to the hippocampal (HPC mod 1) model fit (based on the RMSE and  
 466 *adjusted-R<sup>2</sup>*). In the CB (cerebellar volume as the response variable) and putamen (putamen  
 467 volume as the response variable) volume models, insignificant predictors were retained because  
 468 they contributed more to model fit of the data (based on the RMSE and *adjusted-R<sup>2</sup>*).

**TABLE 3: Linear regression model results**

Mod name (n; intercept)	Effect	Est.	SE	t-value	$\beta$	95% CI	p
HPC mod 1 (45; .53)	THAL	.48	.12	4.0	.44	.23, .72	= .0003***
	AD	-.1	.022	-4.4	-	-.15-.05	< .0001***
	MCI	-.08	.023	-3.4	-	-.13, -.03	= .001**
<i>AIC = -118; RMSE = .06; NRMSE=.66; F (3,41) = 16.8, p &lt; .0001***; <math>\Delta R^2 = .52</math></i>							
HPC mod 2 (45; .54)	THAL	.44	.12	3.7	.41	.2, .68	= .0007***
	CDR	-.1	.02	-4.9	-	-.14, -.06	< .0001***



$AIC = -119$ ;  $RMSE = .06$ ;  $NRMSE = .67$   $F(2,42) = 25.2$ ,  $p < .0001^{***}$ ;  $\Delta R^2 = .52$

PUT mod (45; .57)	<b>THAL</b>	<b>.38</b>	<b>.12</b>	<b>3.2</b>	<b>.53</b>	<b>.15, .60</b>	<b>&lt; .01 **</b>
	Age	.0022	.0011	1.9	.28	0, .004	= .06
	CB	-.0173	.0101	-1.7	-.28	-.04, .00	= .10
	<b>CB: Age</b>	<b>.0026</b>	<b>.0013</b>	<b>2.1</b>	<b>.30</b>	<b>0, .01</b>	<b>= .046*</b>

$AIC = -136$ ;  $RMSE = .05$ ;  $NRMSE = .80$ ;  $F(4,40) = 4.6$ ,  $p = .004^{**}$ ;  $\Delta R^2 = .25$

CB mod (45; 8.8)	<b>THAL</b>	<b>6.3</b>	<b>1.8</b>	<b>3.5</b>	<b>.55</b>	<b>2.75, 9.85</b>	<b>&lt; .01 **</b>
	PUT	-3.6	2.1	-1.71	-.22	-7.7, -.52	= .09
	HPC	1.8	1.55	1.15	.17	-1.2, 4.8	= .25

$AIC = 106$ ;  $RMSE = .70$ ;  $NRMSE = .76$ ;  $F(3,42) = 9.2$ ,  $p < .0001^{***}$ ;  $\Delta R^2 = .36$

LV mod <sup>T</sup> (45; 2.4)	<b>THAL</b>	<b>-3.08</b>	<b>.461</b>	<b>-6.68</b>	<b>-.69</b>	<b>-3.9, -2.2</b>	<b>&lt; .0001 ***</b>
	<b>Age</b>	<b>1.47</b>	<b>.007</b>	<b>3.1</b>	<b>.28</b>	<b>.45, 2.5</b>	<b>&lt; .01 **</b>

$AIC = 35$ ;  $RMSE = .33$ ;  $NRMSE = .61$ ;  $F(2,42) = 34.1$ ,  $p < .0001^{***}$ ;  $\Delta R^2 = .61$

THAL mod 1 (45; .72)	<b>PUT</b>	<b>.313</b>	<b>.132</b>	<b>2.4</b>	<b>.22</b>	<b>.05, .57</b>	<b>= .023*</b>
	<b>HPC</b>	<b>.213</b>	<b>.097</b>	<b>2.2</b>	<b>.23</b>	<b>.02, .40</b>	<b>= .034*</b>
	<b>LAT VENT</b>	<b>-.0235</b>	<b>.006</b>	<b>-3.9</b>	<b>-.44</b>	<b>-.04, -.01</b>	<b>= .0003 ***</b>
	<b>CB</b>	<b>.023</b>	<b>.0095</b>	<b>2.4</b>	<b>.26</b>	<b>.00, .04</b>	<b>= .02*</b>

$AIC = -139$ ;  $RMSE = .05$ ;  $NRMSE = .56$ ;  $F(4,40) = 21.2$ ,  $p < .0001^{***}$ ;  $\Delta R^2 = .65$

THAL mod 2 (45; .71)	<b>PUT</b>	<b>.29</b>	<b>.13</b>	<b>2.2</b>	<b>.21</b>	<b>.04, .56</b>	<b>= .031*</b>
	<b>HPC</b>	<b>.22</b>	<b>.094</b>	<b>2.3</b>	<b>.24</b>	<b>.03, .40</b>	<b>= .025*</b>
	<b>HPC: Age</b>	<b>-.031</b>	<b>.0144</b>	<b>-2.14</b>	<b>-.25</b>	<b>-.06, -.01</b>	<b>= .04*</b>
	<b>CB</b>	<b>.026</b>	<b>.009</b>	<b>2.8</b>	<b>.30</b>	<b>.008, .04</b>	<b>= .009 **</b>
	<b>LAT VENT</b>	<b>-.02</b>	<b>.006</b>	<b>-3.2</b>	<b>-.38</b>	<b>-.03, -.01</b>	<b>= .002 **</b>
	<b>Age</b>	<b>-.0015</b>	<b>.0012</b>	<b>-1.2</b>	<b>-.13</b>	<b>-.004, 0</b>	<b>= .23</b>


$AIC = -140$ ;  $RMSE = .04$ ;  $NRMSE = .53$ ;  $F(6,38) = 13.1$ ,  $p < .0001^{***}$ ;  $\Delta R^2 = .67$

469  
470  
471  
472  
473  
474  
475

$\Delta R^2$  = adjusted R2  $AIC$  = Akaike's Information Criterion;  $\beta$  = standardized coefficient; Effect = variable name; CB:Age = cerebellar by age interaction higher order term; Est = coefficient; F = F-statistic; HPC = hippocampal normalized volume; LV = lateral ventricle; mod = model  $NRMSE$  = normalized RMSE; PUT = putamen normalized volume; THAL = normalized thalamic volume; CB = normalized cerebellar volume; <sup>T</sup> = log transformed dependent and explanatory variables. All values are rounded. All continuous predictors were centered in the THAL mod 2, which included a HPC by age interaction; all continuous predictors were also centered in the PUT model, which included an CB by age interaction.

476 FIG 3 effects plots are for each model's most important continuous predictors. Effects  
477 plots use partial residuals, meaning that while each plot is derived from a complete model (i.e.,  
478 the models in **Tables 3**), variables other than the effect of interest plotted are controlled for (64).  
479 FIG 3 includes two effects plots for the thalamic volume model: thalamic volume on  
480 hippocampal volume (FIG 3B), and thalamic volume on lateral ventricular volume (FIG 3E).  
481 Thalamic volume as an explanatory variable had consistently the greatest effect. Four of six plots  
482 in FIG 3 help to convey the explanatory effect of thalamic volume in linear models, where  
483 volume of one of the other structures was the response variable.

484



485 **FIG 3:** Effects plots: The effects plots use partial residuals, such that while each plot is derived from a complete model, variables  
486 other than the effect of interest plotted are controlled for. A = hippocampal (HPC) on thalamic volume, B = thalamic (THAL) on HPC  
487 volume, C = cerebellar (CB) on THAL volume, D = lateral ventricular (LV) on THAL volume, E = thalamic (THAL) on LV volume, F  
488 = putamen (PUT) on THAL volume. All volume measures are normalized and relative as a % total intracranial volume.  
489

490

#### 491 4.2 Model interpretation

492 In brief example interpretations, with respect to the HPC mod 1, **Table 3**, controlling for group  
493 (AD and MCI group membership), a unit increase in thalamic volume explained a .48% increase  
494 (.48% of intracranial volume [ICV]) in hippocampal volume that was statistically significant,  $p =$   
495 .0003. Holding thalamic volume as well as the MCI group membership constant, AD group  
496 membership explained a .1% decrease in mean hippocampal volume relative to controls, a  
497 difference that significantly differed from zero,  $p < .0001$ . Holding thalamic volume as well as  
498 AD group membership constant, MCI group membership explained a .08% decrease in mean  
499 hippocampal volume relative to controls, a difference that significantly differed from zero,  $p =$   
500 .001. Inputting the grand mean thalamic volume of .72% into the model (HPC mod 1), the model  
501 estimated hippocampal volume marginal means (means predicted by the fitted model) were as  
502 follows: AD .43% (95% CI .40, .46), MCI .45% (95% CI .42, .48), CN.52% (95% CI .50, .56). A  
503 Tukey test indicated mean hippocampal volume was significantly reduced in AD ( $M = .43\%$ ,  
504  $SD = .08$ ) versus controls ( $M = .52\%$ ,  $SD = .07$ ),  $p < .001$ ,  $d = -1.6$ , and in MCI ( $M = .45\%$   $SD = .06$ )  
505 versus controls ( $M = .52\%$ ,  $SD = .07$ ),  $p < .01$ ,  $d = -1.6$ . There was no significant difference  
506 between AD and MCI model means,  $p > .05$ . Note also that a binarized version (see Methods) of  
507 cognitive dementia rating (CDR) had a similar effect to the group variable (AD vs. control)  
508 explaining hippocampal volume.

509 With regard to log transformed<sup>(52)</sup> lateral ventricular model, holding thalamic volume  
510 constant, for every 10% increase in age (range 56 to 88) lateral ventricular volume increased by  
511 about 15% (of total intracranial volume [ICV]), which significantly differed from zero,  $t(42) =$   
512 2.8,  $p = .007$ ; holding age constant, every 10% increase in thalamic volume explained a lateral  
513 ventricular volume decrease of about 25% (of ICV),  $t(42) = -6.68$ ,  $p < .0001$ . The latter reflects,  
514 for the most part, the anatomical thalamus-lateral ventricular juxtaposition: the superior aspect

515 of the thalamus forms much of lateral ventricular inferior border or floor <sup>(65)</sup>. The comprehensive  
 516 test suite <sup>(63)</sup> for assumptions indicated no violations of assumptions. Converting the model log  
 517 coefficients back to original values, inputting the average age of 73.3 and grand mean for  
 518 thalamic volume of .72%, the predicted lateral ventricular mean volume (based on uncentered  
 519 predictors in this case) was 2.4% (of ICV) (95% CI 2.1, 2.6).

### 520 5.1 Bivariate repeated-measures analysis

521 **Table 4** summarizes the repeated measures strength and direction of association between  
 522 structure volume and a given predictor. All values represent bivariate repeated-measures  
 523 correlations ( $r_{rm}$ ) ignoring groups. As noted in section 2.5, the  $r_{rm}$  coefficients have a -1 to 1  
 524 index of between variable association strength analogous to Pearson  $r$ , but unlike Pearson  $r$  the  
 525  $r_{rm}$  calculation does account for the non-independence of repeated-measures <sup>(43)</sup>.

**TABLE 4: Bivariate repeated-measure correlations ( $r_{rm}$ ),  $N=36$  (108 data points over 3 time points)**

Variable	HPC Vol	PUT Vol	THAL Vol	LAT VENT Vol	CB Vol
	$r_{rm}$ (df), 95% CI (), p-value	$r_{rm}$ (df), 95% CI, p-value	$r_{rm}$ (df), 95% CI, p-value	$r_{rm}$ (df), 95% CI, p-value	$r_{rm}$ (df), 95% CI, p-value
<b>HPC Vol</b>		$r_{rm}(71) = .45$ (.24, .62), $p < .0001$	$r_{rm}(71) = .74$ (.61, .83), $p < .0001$	$r_{rm}(71) = -.68$ (-.79, -.54), $p < .0001$	$r_{rm}(71) = .22$ (-.01, .43), $p = .06$
<b>PUT Vol</b>			$r_{rm}(71) = .60$ (.42, .73), $p < .0001$	$r_{rm}(71) = -.39$ (-.57, -.17), $p < .001$	$r_{rm}(71) = .26$ (.03, .46), $p = .03$
<b>THAL Vol</b>				$r_{rm}(71) = -.55$ (-.68, -.36), $p < .0001$	$r_{rm}(71) = .001$ (-.23, .23), $p = .99$
<b>LAT VENT Vol</b>					$r_{rm}(71) = -.43$ (-.60, -.22), $p < .001$
<b>Age</b>	$r_{rm}(71) = -.63$ , (-.76, -.47), $p < .0001$	$r_{rm}(71) = -.27$ , (-.47, -0.04), $p = .02$	$r_{rm}(71) = -0.46$ , (-.62, -.25), $p < .0001$	$r_{rm}(71) = .75$ , (.63, .84), $p < .0001$	$r_{rm}(71) = -.30$ , (-.50, -.07), $p = .009$
<b>CDR</b>	$r_{rm}(71) = -.43$ , (-.6, -.22), $p < .001$	$r_{rm}(71) = -.23$ (-.44, .001), $p = .048$	$r_{rm}(71) = -.33$ , (-.52, -.1), $p = .005$	$r_{rm}(71) = .46$ , (.26, .63), $p < .0001$	$r_{rm}(71) = -.13$ , (-.35, .11), $p = .27$

MMSE	$r_m(71) = .32, (09, .51),$ $p < .01$	$r_m(71) = 0.22,$ (0.04 0.47), $p = .055$	$r_m(71) = 0.27,$ (.03, .47), $p = .02$	$r_m(71) = -.36,$ (-.54, -.14), $P = .002$	$r_m(71) = 0.25,$ (.02, .46), $p = .03$
------	--	---	---	--	---

526 CB = cerebellum; HPC= hippocampus; PUT = putamen; THAL = thalamus; LAT VENT = lateral ventricles;  
527  $r_m$  = repeated-measures correlation coefficient (Bakdash, Marusich, 2017); Vol = normalized volume. Strong effect correlations  
528 ( $r_m \geq .60$ ) are in bold  
529  
530  
531

## 532 6.1 Longitudinal analysis


533 This section reviews the mixed model analyses for longitudinal volume analysis of  
534 hippocampal, putamen, thalamic, cerebellar, and lateral ventricular structures across the three  
535 time points: baseline, 12 months and 24 months. See section 2.5.2 *Linear mixed model methods*  
536 for methodological details. Longitudinal findings begin with a short summary of annualized  
537 volume results. This is followed by graphs, then the tabulated mixed model details are reviewed.  
538 Finally, an example model interpretation is provided focusing on the longitudinal hippocampal  
539 volume model. Additional model details, including comparisons of each model type (1-7: see  
540 2.5.2 *Linear mixed model methods*) are provided in *Supporting information I*. Note, in aid of  
541 reducing this article length, mixed model diagnostics, which included fixed and random effects  
542 assessments, are provided in *Supporting information VI*. All final models complied with mixed  
543 model regression assumptions.

544 Note, some subjects did not have measures at 12- and 24-month times. In addition, to  
545 comply with model diagnostic findings (see *Supporting information VI*) a few more data  
546 instances were removed (see **Tables 5, 6** for each structure's model  $n$ -count). To reduce risk of  
547 overfitting, all mixed models complied with the relaxed one predictor to five data instance rule of  
548 thumb <sup>(57)</sup>.


549           The assessment of median annualized percentage volume change over a period of two  
550 years was completed subsequent to the mixed model analysis, and provides another perspective  
551 of volume change over time. To be consistent with the mixed model findings, this calculation  
552 (see *Statistics 2.5*) included a group breakdown only for hippocampal and thalamic annualized  
553 percentage volume change calculations. The best fitting hippocampal and thalamic mixed  
554 models, as reviewed below, retained the group (AD, CN, MCI) variable; the best fitting  
555 cerebellar, putamen and lateral ventricular mixed models, however, did not retain the group  
556 variable, and annualized percentage volume change for these structures was assessed without  
557 specifying group. The hippocampal and thalamic median annualized percentage volume change  
558 (by group) clearly followed the AD > MCI > CN pattern of greater annualized volume reduction.  
559 Hippocampal median annualized volume change (by group) ranged from -4.7% in AD to -.88%  
560 in controls. Median annualized thalamic volume change (by group) ranged from -1.3% in AD to  
561 -.62% in controls. The heightened hippocampal volume change in AD amounted to about 2.5  
562 times the annual reduction in MCI; change in MCI, reduction in hippocampal volume, amounted  
563 to 2 times that found in controls. The extent of thalamic volume reduction in AD was about 1.6  
564 times the annual reduction in MCI and about 2 times the annual reduction that occurred in  
565 controls. The median annualized percentage change, not specified by group, for cerebellar,  
566 putamen and lateral ventricular volume was -.60, 0, and 6.8 respectively. Details are provided in  
567 *Supporting Information II* (see Tables S2-1 and S2-2).

568           FIGs 4 and 5 reveal the longitudinal (2-year) pattern in the volumetric data. FIG 4  
569 (Trellis) plots, panels A to E, are based on 108 data instances, 36 at each time point (see Table 2  
570 for the group breakdown). They convey the trend in structure volume change over time for each  
571 subject. Specifically, the random, individual subjects' intercepts (volume means) from baseline

572 to 24 months are provided; individual structure volume is regressed on time. The upper panel  
573 area in each of these plots has the subject anonymized identification number; a regression line in  
574 each subject's plot shows the slope (ordinary least squares estimated line for a given subject  
575 panel), which, here, is the subject volume extent of change at each time-point, and the intercept  
576 representing the average, normalized volume for each subject. Close inspection of FIG 4 shows  
577 hippocampus (A) and thalamic (B) volume with largely linear decreases in volume over time.  
578 The cerebellum (C) has a similar pattern of volume decrease over time and the putamen (D) has  
579 a less distinct pattern of volume change over time. The lateral ventricle (E) volume generally  
580 increases linearly over time.



581




**FIG 4 Lattice plots:** Individual subject intercepts (volume) and time trends. A = hippocampus (HPC); B = thalamus (THAL); C = cerebellum (CB); D = putamen (PUT); E = lateral ventricles (LV). Y-axis is the structure's percentage of total intracranial volume, plotted against time: 0 to 24 months. Numbers inside and at the top of each panel are subject identifiers. Data for each subject are provided in an individual panel along with a simple linear regression line. Considerable variation of random subject intercepts over time is evident.

582

583

584 Longitudinal baseline (0) to 24-month (spaghetti) plots are provided in FIG 5. Thicker lines are  
 585 the group mean. The thick group mean lines help to clarify patterns: e.g., note the largely  
 586 antithetical hippocampal (A) and lateral ventricular (E) volume change patterns particularly  
 587 evident in the AD group.





588

589

590

591

592

593

FIG 5: Spaghetti plots: Y-axes show normalized volume converted to z-scores; x-axes show time, baseline to 24 months (baseline = 0). (A) hippocampus (HPC); (B) cerebellum (CB); (C) thalamus (THAL); (D) putamen (PUT); (E) lateral ventricles (LV). AD = Alzheimer's, CN = controls, MCI = mild cognitively impaired. Thicker lines are group means.

594  
595  
596 *6.2 Mixed model results*

597 The mixed longitudinal models examined change, if any, in structure volume related to the fixed  
598 effects of passage of time (baseline, 12 months, 24 months), baseline age, and group (AD, CN,  
599 MCI) membership. Random effects assessed were the subject intercept (equivalent to individual  
600 subject variation of intercept) and the subject random slope of time (an indication of extent the  
601 effect of time varies per subject). Details are tabulated in **Tables 5** and **6**. The normalized  
602 volume of each structure broken down by group and time was provided in **Table 2**. A quadratic  
603 term for the fixed effect of time was initially included in models of each structure. However, a  
604 quadratic term significantly contributed to only the lateral ventricular model and was only  
605 retained in the lateral ventricular model. A version of the hippocampal volume mixed model  
606 included an interaction (see *Supporting Information I*, Table S1-1). However, this interaction  
607 was not tabulated in the results section because there were too few data instances to formally  
608 support this more complex model.

609 An example interpretation is provided in section 6.3, which focuses on the hippocampal  
610 mixed model results. The hippocampal model predicted means are also provided in section 6.3.  
611 The predicted thalamic volume means at baseline mean age and at all three time-points were as  
612 follows for each group. Controls: baseline time, .746 (95% CI .705, .786); 12 months,.739 (95%  
613 CI .699, .779); 24 months, .732 (95% CI .692, .771). MCI: baseline time, .679 (95% CI .637,  
614 .722); 12 months,.672 (95% CI .630, .714); 24 months, .665 (95% CI .623, .707). AD: baseline  
615 time, .690 (95% CI .645, .734); 12 months, .682 (95% CI .638, .727); 24 months, .675 (95% CI  
616 .632, .719). Here, all confidence intervals overlap, and while this is often an indication of non-  
617 significant group differences, such is not always the case. Indeed, pairwise tests indicated that

618 the MCI and control group marginal means significantly differed as determined by a Tukey test,  
 619  $z = -2.6, p = .03, d = -.83$ . AD vs. MCI did not significantly differ ( $z = -0.38, p = .92, d = -.63$ ),  
 620 nor did AD vs. controls ( $z = -2.12, p = .09, d = -.74$ ).

621 The model predicted volume means for the cerebellum, putamen, and lateral ventricles  
 622 were as follows. The cerebellum, in addition to random effects, retained only the fixed effect of  
 623 time. The predicted cerebellar volume mean was 8.87% (95% CI 8.6, 9.2) at baseline time,  
 624 8.79% (95% CI 8.5, 9.1) at 12 months, and 8.70 (95% CI 8.4, 9) at 24 months. The putamen  
 625 model predicted mean (amounting to the intercept in this case given no fixed effects were  
 626 retained in the best model, just random effects) was .57 (95% CI .55, .59). The lateral ventricular  
 627 best fitting model retained the fixed effect of time, coupled with a time quadratic term ( $\text{time}^2$ ),  
 628 and baseline age (in addition to the random effects, but not group). Model predicted means were  
 629 2.60% (95% CI 2.2, 3.0) at baseline, 2.84% (95% CI 2.43, 3.26) at 12 months, and 3.07% (95%  
 630 CI 2.63, 3.51) at 24 months.

**TABLE 5: Mixed models: hippocampal and putamen volume**

Model name ( <i>n</i> ; data points)							
<i>HPC mod MT6</i> (35; 105)	Effect	Est.	SE	t-value	$\beta$	95% CI	<i>p</i>
<u>FIXED effects</u> ; intercept: .537							
	AD	-0.13	0.025	-5.3	-	-.19, -.08	< .0001 ***
	MCI	-.10	.023	-4.2	-	-.14, -.04	< .001**
	Time	-.011	.002	-5.8	-.1	-.014, -.007	< .0001 ***
	Age	-.0034	.0015	-2.2	-.27	-.006, -.0003	= .03
<u>RANDOM effects</u>							
	<i>SD</i>			$\chi^2$		95% CI	<i>p</i>
Intercept <sup>a</sup>		.06		194		.05, .07	< .0001***
Slope <sup>a</sup>		.009		9.6		.006, .013	= .002**
<i>AIC = -468; DF = 35; RMSE = .006; NRMSE = .07; deviance = -486; <math>pR^2 m = .53</math>; <math>pR^2 c = .99</math></i>							
<u><i>PUT mod MT3</i> (34; 102)</u>							
	Effect	Est.	SE	t-value	$\beta$	95% CI	<i>p</i>

<u>Fixed effects</u> ; intercept: .571				
<u>RANDOM effects</u>	<i>SD</i>	$\chi^2$	<i>95% CI</i>	<i>p</i>
Intercept <sup>a</sup>	.048	175	.04, .06	< .0001***
Slope <sup>a</sup>	.01	14	.006, .012	< .001**

AIC = -491; DF = 34; RMSE = .005; NRMSE = .10; deviance = -501; pR<sup>2</sup> m = nil; pR<sup>2</sup> c = .97

<sup>a</sup> = subject random effects of intercept and slope of time; Age = centered baseline age; AD = Alzheimer's group (dummy) hippocampal volume relative to control group volume; pR<sup>2</sup> = pseudo r-squared (Kamil Bartoń (2020), pR<sup>2</sup> m = pseudo r-squared fixed effect portion, pR<sup>2</sup> c = total pseudo r-squared; AIC= Akaike's Information; Criterion; β = standardized coefficient; Est = coefficient; HPC = Hippocampal normalized volume; MCI =mild cognitively Impaired group (dummy) hippocampal volume relative to control group volume; NRMSE= normalized RMSE; obs. = observations; PUT= putamen normalized volume; MT = model type 1 to 7 (see section 2.5 for details); mod = model,  $\chi^2$ = Chi-squared. All continuous predictors were centered as interactions were assessed, and all values are rounded.

**TABLE 6: Mixed models: thalamic, cerebellar and lateral ventricular volume**

<b>Model name (n; data points)</b>							
<b>THAL MT6 (33; 99)</b>	<i>Effect</i>	<i>Est.</i>	<i>SE</i>	<i>t-value</i>	$\beta$	<i>95% CI</i>	<i>p</i>
<u>FIXED effects</u> ; (intercept:.703)	AD	-.056	.026	-2.1	-	-.11, -.002	=.04
	MCI	-.066	.026	-2.6	-	-.12, -.10	= .01
	Time	-.0071	.0014	-5.2	-.07	-.009, -.004	< .0001**
	Age	-.0049	.0016	-3.1	-.42	-.01, -.004	= .004
<u>RANDOM effects</u>	<i>SD</i>			$\chi^2$		<i>95% CI</i>	<i>p</i>
	Intercept <sup>a</sup>	.06		208		.05, .08	< .0001 ***
	Slope <sup>a</sup>	.003		.6		.001, .01	= .45
AIC = -451; DF = 33; RMSE =.008; NRMSE =.097; deviance =-469; pR <sup>2</sup> m =.32; pR <sup>2</sup> c = .98							
<b>CB MT4 (35; 105)</b>	<i>Effect</i>	<i>Est.</i>	<i>SE</i>	<i>t-value</i>	$\beta$	<i>95% CI</i>	<i>p</i>
<u>FIXED effects</u> ; (intercept:8.78)	Time	-.0854	.027	-3.2	-.08	-.13, -.03	= .003
<u>RANDOM effects</u>	<i>SD</i>			$\chi^2$		<i>95% CI</i>	<i>p</i>
	Intercept <sup>a</sup>	.845		179		.67, 1.1	< .0001 ***
	Slope <sup>a</sup>	.12		5.3		.07, .19	= .02 *
AIC = 97; DF = 35; RMSE =.118; NRMSE =.12; deviance =85; pR <sup>2</sup> m =.007; pR <sup>2</sup> c = .97							
<b>LV MT5 (36; 108)</b>	<i>Effect</i>	<i>Est.</i>	<i>SE</i>	<i>t-value</i>	$\beta$	<i>95% CI</i>	<i>p</i>
<u>FIXED effects</u> ; (intercept: 2.8)	Time	.212	.028	7.5	.12	.16, .27	< .0001 ***
	Time <sup>2</sup>	.045	.019	2.4	.015	.01, .08	= .03
	Age	.11	.0283	3.8	.50	.05, .17	= .0008
<u>RANDOM effects</u>	<i>SD</i>			$\chi^2$		<i>95% CI</i>	<i>p</i>
	Intercept <sup>a</sup>	1.2		236		.95, 1.5	< .0001 ***

631  
632  
633  
634  
635  
636  
637  
638  
639

Slope <sup>a</sup>	.16	28	.11 .20	< .0001 ***
<hr/> <i>AIC = 105; DF = 36; RMSE = .06; NRMSE = .05; deviance = 83; pR<sup>2</sup>m = .27; pR<sup>2</sup>c = .99</i> <hr/>				

640 <sup>a</sup> = subject random effects of intercept and slope of time; Age = centered baseline age; AD = Alzheimer's group (dummy) thalamic  
641 volume relative to control group volume; pR<sup>2</sup>= pseudo r-squared (Kamil Bartoň (2020), pR<sup>2</sup>m = pseudo r-squared fixed effect portion,  
642 pR<sup>2</sup>c = total pseudo r-squared; AIC= Akaike's Information; Criterion; β = standardized coefficient; CB = normalized cerebellar volume;  
643 Est = coefficient; HPC = Hippocampal normalized volume; LV = lateral ventricular normalized volume; MCI =mild cognitively Impaired  
644 group (dummy) thalamic volume relative to control group volume; NRMSE= normalized RMSE; obs. = observations; PUT= putamen  
645 normalized volume ; MT = model type 1 to 7 (see section 2.5 for details); THAL =normalized thalamic volume; Time<sup>2</sup>= quadratic term  
646 for time; CB = normalized cerebellar volume; mod = model, χ<sup>2</sup>= Chi-squared. All continuous predictors were centered and all values  
647 are rounded.  
648

### 649 6.3 Hippocampal mixed model analysis and interpretation

650 The final saturated model, model type 6 in this case, included fixed effects of time, baseline age,  
651 group (AD, CN, MCI), and random effects of subject intercept and time. Subject random effects  
652 remained significant. This indicates that individual differences (random effects) were not  
653 completely accounted for by the fixed effects (time and group). As indicated in the random  
654 effects portion of the hippocampal model (HPC mod MT6) **Table 5**, over time, both the subject  
655 means (the intercept) and slope of time (varying effect of time) remained significant in the  
656 saturated model type 6. Comparisons of the model types 1-7 (based on AIC, BIC, loglikelihood  
657 and p-values) is provided in Supporting information I (Table S1-1).

658 Hippocampal mixed model results in **Table 5** is consistent with FIGs 2 (A) and 5 (A). A  
659 greater decrease in volume over time is evident in FIG 5 for AD and MCI groups relative to  
660 controls. Also, conveyed in FIG 5 (A), hippocampal (normalized) volume against time was not  
661 constant but appeared to depend on group, indicating that the volume change per each 12-month  
662 interval (across baseline, 12 months, and 24 months) varied by group (an interaction). A  
663 significant ( $p = .003$ ) AD group by time higher order term is reported in Table S1-2 (model 7  
664 type, see *Supporting information I*). However, as already noted, the sample size was too small to  
665 reliably support the inclusion of an additional term, here the higher order term of the model 7  
666 type derived from the group by time interaction. As such, a less complex additive model 6 type is

667 reported in **Table 5**. Notwithstanding the potential of an interaction persisting in a larger data  
668 set, FIG 2 (A) and FIG 5 (A) indicate the control and MCI hippocampal volume means were, at  
669 each time-point for most subjects, above the AD mean. This is one indication that outcome was  
670 not driven by an interaction, and the main effects (HPC mod MT6, **Table 5**) warrant comment.

671       Elaborating briefly on the main effects of model type 6 (no interaction), controlling for  
672 group, the overall effect of a year's passage of time, on average, significantly predicted a 0.011%  
673 (95% CI -.014, -.007) decrease ( $\approx .01\%$  of ICV) per year in hippocampal volume,  $t(35) = -5.8$ ,  $p$   
674  $< .0001$ . Controlling for time, baseline age and MCI group membership, AD group membership,  
675 relative to controls, significantly predicted a 0.13% (95% CI -.19, -.08) decrease in hippocampal  
676 volume,  $t(35) = -5.3$ ,  $p < .0001$ . Controlling for time, baseline age, and AD group membership,  
677 MCI group membership, relative to controls, significantly predicted a .10% volume (95% CI -  
678 0.14, -0.04) decrease,  $t(35) = -4.2$ ,  $p < .001$ . Finally, controlling for other predictors, baseline age  
679 significantly predicted a .003% (95% CI -.006, -.0003) decrease in hippocampal volume,  $t(35) =$   
680  $-2.2$ ,  $p = .03$ . Lending some perspective to the standardized coefficients, and using baseline age  
681 as an example, there was a .27 standard deviation reduction in hippocampal volume per year of  
682 age. This constitutes about a .02% ( $SD$  hippocampal volume = .087;  $.27 * .087 = .02$ ) decrease  
683 per year of hippocampal volume as derived from baseline age. The marginal (fixed effect  $pR^2m$ )  
684 pseudo  $R^2$  (54) for this model was .53 (i.e., 53% of pseudo variance, not actual variance, was  
685 explained by the model) and the composite fixed and random effects ( $pR^2c$ ) was .99. The RMSE  
686 and NRMSE for this longitudinal hippocampal volume analysis were relatively small and the  
687 pseudo  $R^2$  for the fixed effects ( $pR^2m$ ) was relatively high.

688       The group predicted marginal means (average fitted marginal, by group, means) of  
689 hippocampal volume at mean baseline age and at all three time-points were as follows for each

690 group. Controls: baseline time, .548 (95% CI .511, .584); 12 months,.537 (95% CI .501, .573);  
691 24 months, .526 (95% CI .490, .563). MCI: baseline time, .446 (95% CI .408, .484); 12  
692 months,.436 (95% CI .398, .474); 24 months, .425 (95% CI .387, .463). AD: baseline time, .413  
693 (95% CI .411, .455); 12 months,.402 (95% CI.361, .444); 24 months, .392 (95% CI .350, .433).  
694 Note, the confidence intervals for AD and controls do not overlap, nor the confidence intervals  
695 for controls and MCI; one indication that both AD and MCI groups significantly differ from  
696 controls. On the other hand, the AD and MCI confidence intervals do overlap, an indicator of  
697 lack of significant difference between AD and MCI hippocampal volumes.

698 In post hoc pairwise comparisons using a Tukey test, AD members had significantly  
699 lower hippocampal volume compared to controls,  $z = -5.3$ ,  $p < .0001$ ,  $d = -1.9$ . This  $d$ -value  
700 indicates a large negative effect of AD group membership on hippocampal volume. MCI  
701 hippocampal volume also significantly differed from controls,  $z = -4.2$ ,  $p < .0001$ ,  $d = -1.56$ .  
702 Again, as with the AD group, this  $d$ -value indicated MCI group membership had a large negative  
703 effect on hippocampal volume. There was no significant hippocampal volume difference  
704 between AD and MCI groups,  $z = 1.2$ ,  $p = .23$   $d = -.62$ .

## 705 **Discussion**

706 Utilizing subcortical structure volume as the primary measure of interest in AD and  
707 normal aging, the current work was a composite study uniquely combining three phases of  
708 research. Initially, a platform dedicated to volumetry analysis, volBrain<sup>(42)</sup>, was used for the  
709 automated segmentation/volume calculation of five structures: cerebellum, putamen,  
710 hippocampus, lateral ventricles and thalamus. After a reliability assessment of volBrain volume  
711 estimates, linear regression and linear mixed longitudinal regression analyses were conducted.  
712 The test-retest reliability of volBrain segmented same-subject scans, was high, as indicated by

713 the mean ICC score of .989 ( $SD = .012$ ). The lowest ICC was .937 (95% CI .829, .978). For  
714 details on all ICC measures see **Table S1-11** in *Supporting Information I*.

715         There were a few salient, notable findings. First, linear models demonstrated thalamic  
716 volume had consistently the greatest explanatory effect of volume in the other structures: the  
717 hippocampus, putamen, cerebellum and lateral ventricles. Second, in longitudinal mixed models,  
718 the group variable AD and MCI cohorts (that served as proxies for early AD and MCI  
719 respectively) significantly contributed to the best-fitting hippocampal and thalamic models but  
720 not to the best fitting putamen, cerebellar or lateral ventricular models. Third, longitudinal mixed  
721 models indicated time (1 year) had a negative effect on hippocampal, cerebellar and thalamic  
722 volume, a positive effect on lateral ventricular volume, and no effect on putamen volume;  
723 baseline age had no effect on cerebellar or putamen volume, a negative effect on hippocampal  
724 and thalamic volume, and a positive effect on lateral ventricular volume. Model findings will be  
725 reviewed after a summary paragraph highlighting annualized volume change results.

726         It warrants mention that the use of linear models should not be construed to imply  
727 necessarily linear response–predictor relationships. Indeed, in the lateral ventricular linear  
728 volume model (based on baseline data, baseline lateral ventricular volume being the response  
729 variable) a decidedly nonlinear response–explanatory variable relationship was addressed by a  
730 log transform of the response variable ventricular volume (see *4.1 Linear regression volume*  
731 *analyses*). Nevertheless, regression models were used because of their high interpretability and  
732 broad adoption for quantifying variable relationships. In addition, violation of linearity did not  
733 occur in models of other structures, nor was there a quadratic shape to the baseline data. In the  
734 longitudinal data (just 2-years total time), the mixed model for lateral ventricular volume



735 demonstrated a slight but significantly improved fit by addition of a quadratic term; an indication  
736 of some nonlinear change (specifically slight acceleration, expansion) in lateral ventricular  
737 volume over time. Finally, it also warrants underlining that, as specified in section 2.5, model  
738 results reflect regression not mediation analyses; coefficients quantify the magnitude/strength of  
739 the predictor/explanatory/independent variable effect to explain outcome (volume of a given  
740 structure). Variables were not assessed as (causal) mediators. For example, in the linear  
741 regression analyses thalamic volume as a predictor had consistently the largest coefficient/effect  
742 magnitude. This does not validate the thalamus as a causal mediating variable of outcome.

743 Hippocampal median annualized volume change (see *Supporting information II*, Tables  
744 S1-S2), was in agreement with prior research (2, 4, 6, [66](#)), and followed an AD > MCI > CN  
745 volume atrophy pattern, with an annual AD hippocampal atrophy of 4.7% that paralleled meta-  
746 analytic review findings of 4.66% ([66](#)). Similarly, the pattern of annualized thalamic volume  
747 change (reduction) followed the same atrophy AD > MCI > CN pattern. In annualized normal  
748 aging (controls in the current work), and consistent with other research ([67-69](#)), there was  
749 cerebellar, thalamic and particularly hippocampal volume reduction, but lateral ventricular  
750 volume increase. In normal aging, however, our lack of change in putamen volume differed from  
751 the Fjell et al. ([67](#)) findings, but was in agreement with another study ([22](#)). Of relevance, the Fjell et  
752 al. research used a much larger sample ( $N = 1100$ ) compared to our project or the Cousins et al.,  
753 ([22](#)) study. In addition, in yet other longitudinal research ( $N = 883$  ([67](#))), the putamen also exhibited  
754 volume reduction ([69](#)). It seems likely that the putamen, relative to the other structures, simply  
755 requires more data to detect notable volume change. Of note, cerebellum annualized volume  
756 change (see section 6.1) was very small (.60 %), an outcome accounted for by slight cerebellar  
757 decline in AD as shown in Table 2. This table also suggests that cerebellar volume may be

758 spared in MCI or even greater in MCI. This is in agreement with the consistently higher MCI  
759 cerebellar volume that has been reported relative controls (70). While AD type pathology may  
760 occur in the cerebellum (71), it may also be spared in AD (24). In short, our findings for cerebellar  
761 volume in AD and MCI, like that cited above, are not conclusive. In our mixed model regression  
762 analyses (see section *Longitudinal mixed models* that follows the next section) AD pathology  
763 (via the group variable) did not contribute to cerebellar volume. But the passage of time  
764 significantly contributed to annual reduction in cerebellar volume.

### 765 *Linear regression analyses and the primacy of the thalamus*

766 The linear models explaining putamen and cerebellar volume had the highest RMSE and  
767 NRMSE values but lowest *adjusted-R<sup>2</sup>* values (e.g., putamen volume model, *adjusted-R<sup>2</sup>* = .25,  
768 RMSE = .05; cerebellar volume model *adjusted-R<sup>2</sup>* = .36; RMSE = .70) indicating that the  
769 features (explanatory volume variables, age, CDR or group) and algorithm (linear regression) did  
770 not amount to a good fit of the observations. By contrast, models explaining hippocampal,  
771 thalamic, and lateral ventricular volume had the lowest RMSE and NRMSE but highest *adjusted-*  
772 *R<sup>2</sup>* values (e.g., *adjusted-R<sup>2</sup>* ranged from .52 for a hippocampal volume model to .67 for a  
773 thalamic volume model (see **Table 3** for details). Marginally significant interactions occurred in  
774 the putamen volume linear model and in one of the thalamic linear models. In both instances age  
775 had a moderating but antithetical effect (see *Supporting Information V* for an interpretation).

776           Importantly, in linear model stepwise (backward using AIC) procedures, thalamic  
777 volume, as an explanatory variable, had by far the largest significant estimate in all models (see  
778 **Table 3**), as predicted. Thalamic volume had a positive relationship with hippocampal, putamen,  
779 and cerebellar volume: a unit increase in thalamic volume explained a (conditional) mean

780 structure volume increase ranging from .38% of total intracranial volume (ICV) in the putamen  
781 to 6.3% of ICV in the cerebellum. By contrast, thalamic volume, again as an explanatory  
782 variable, had a negative relationship with lateral ventricular volume largely reflecting its  
783 anatomical location: the dorsal thalamus forms much of the anatomical floor of the lateral  
784 ventricular body (see FIG 1 A). As such, an increase in thalamic volume would encroach on and  
785 reduce ventricular volume. Additionally, the hippocampal volume model retained the group  
786 variable differentiating AD and MCI pathology cohorts relative to controls. Hippocampal  
787 volume mean was significantly reduced in AD and MCI relative to controls (see 4.2 for marginal  
788 means and Tukey test results). It was also originally hypothesized that the best fitting thalamic  
789 model would also retain the group variable (the proxy for AD and MCI pathology); this  
790 hypothesis was not confirmed by the findings.

791 While the thalamus had the largest linear regression coefficients explaining the volume of  
792 other structures, in the model of thalamic volume (thalamic volume as the response variable) the  
793 largest coefficients explaining thalamic volume were those from putamen and the hippocampal  
794 volume, outcomes in concert with both the critical hub-like role of the thalamus <sup>(34)</sup> and the so-  
795 called “rich club network” comprising the thalamus, hippocampus and putamen <sup>(72, 73)</sup>.

796 Moreover, in practical terms, the consistently larger estimates/coefficients of thalamic  
797 volume in the role of explanatory/predictor variable positions thalamic volume as the most “bang  
798 for the buck” estimate of hippocampal, cerebellar, putamen and lateral ventricular volume. As a  
799 single source insight aid of hippocampal, cerebellar, putamen and lateral ventricular volume, the  
800 usefulness of thalamic volume is well demonstrated by the current work findings. Moreover, this  
801 supports use of thalamic volume in clinical imaging assessments where possible, particularly

802 where the target structure is densely interconnected with the thalamus. Noteworthy, evidence  
803 from other research indicates early AD thalamic involvement is confined largely to the anterior  
804 thalamic nuclei <sup>(14)</sup>. As such, using the entire thalamic volume measure likely diminishes the  
805 effect of AD and MCI pathology group membership <sup>(11)</sup>. A next step in the current vein of  
806 research will include imaging data and analyses derived from isolation of particular thalamic  
807 nuclei, such as the anterior thalamic group.

#### 808 *Longitudinal mixed models*

809 In normal aging, mixed models determined time, passage of just a single year, had a  
810 negative effect on hippocampal, cerebellar and thalamic volume, no effect on putamen volume,  
811 and a positive effect on lateral ventricular volume. The effect of time on volume, conveyed in  
812 FIG 2, FIG 5, **Tables** 4, 5, 6 and annualized volume results, is largely consistent with other  
813 research <sup>(4, 67-69)</sup>. As noted earlier in this discussion, the exception was putamen volume. Mixed  
814 model longitudinal putamen volume results had the same null change found in the annualized  
815 putamen volume outcome. Baseline age had a negative effect on hippocampal and thalamic  
816 volume, no effect on cerebellar or putamen volume and a positive effect on lateral ventricular  
817 volume. With the exception of the putamen, these findings are in keeping with other research <sup>(12)</sup>  
818 employing the same segmentation platform. Over the adult life span, a smoothing spline model  
819 captured accelerated change for the lateral ventricles, cerebellum, putamen and particularly the  
820 hippocampus <sup>(67)</sup>. Similarly, over the course of a decade, non-linear patterns of hippocampal and  
821 lateral ventricular volume change have been reported <sup>(69)</sup>. Over the course of a single year,  
822 accelerated hippocampal atrophy measured by quadratic expansion <sup>(6)</sup>, has been reported. The  
823 present work mixed model findings included a small but significant quadratic time term

824 indicative of annual marginally accelerated lateral ventricular volume increase (see **Table 6**).  
825 Specifically, the quadratic term for time was positive (as was the effect of time itself, see **Table**  
826 **6**) indicating a significant incremental effect of time on lateral ventricle volume ( $p = .03$ ). This is  
827 consistent with the FIG 5 (B) lateral ventricular volume plot, where a slight convexity appears  
828 (in the mean thicker loess lines).

829         The best fitting hippocampal and thalamic mixed models retained the group variable, the  
830 proxy of AD or MCI potential AD pathology. The marginal (group) predicted hippocampal  
831 volume means, at baseline age, and for all three time points were significantly ( $p < .05$ ) lower for  
832 both AD and MCI relative to controls. Group predicted hippocampal AD and MCI mean  
833 volumes did not significantly differ. Cohen's  $D$  values (AD,  $d = -1.9$ ; MCI,  $d = -1.56$ ) indicated  
834 large negative effects of AD and MCI group membership on hippocampal volume relative to  
835 controls.

836         Thalamic marginal means were also lower in AD and MCI groups relative to controls,  
837 but only the MCI marginal mean significantly differed ( $z = -2.58$ ,  $p = .03$ ) from controls. While  
838 thalamic AD vs control predicted marginal means did not significantly differ ( $z = -2.12$ ,  $p = .09$ ,  
839  $d = -.74$ ) the Cohen's  $d$  effect sized of  $-.74$  indicates a moderate strength difference between AD  
840 and control group thalamic volume. See *6.2 Mixed model results* for details.

841         Large negative AD and MCI Cohen's  $d$  effect sizes for the hippocampus (sections *4.2*  
842 and *6.3*) indicate proportionally large, negative effects of AD and MCI membership on  
843 hippocampal volume relative to controls. The strength of group membership was not as  
844 pronounced for thalamic volume. This may, at least in part, be due to use of the entire thalamus  
845 volume measure, which, as noted at the end of the section *Linear regression analyses and the*

846 *primacy of the thalamus*, likely diminishes model sensitivity. More pronounced hippocampal  
847 longitudinal volume decline in AD has been previously reported (4: 6: 66, 74), as has greater  
848 thalamic volume decline in AD (4). Retention of the group variable in both the hippocampal and  
849 thalamic models, in the present work, is in keeping with the well documented interconnectedness  
850 of these structures (33, 38, 39), evidence of early AD pathology in both structures (14, 75), and also  
851 consistent with repeated measure correlation findings (see **Table 4**), where the second strongest  
852 correlation ( $r_{rm}(71) = .74, p < .0001$ ) occurred between hippocampal and thalamic volume. Both  
853 AD and MCI thalamic volume have exhibited reduction in other research (4: 15, 16).

854 The present work findings, are in line with research from Braak et al. (13, 14) and Aggleton  
855 et al. (41) indicating early-stage AD type pathology in both hippocampus and thalamus. The  
856 mixed model group variable (again representing AD or MCI pathology relative to controls) was  
857 not retained by best fitting/parsimonious cerebellar, putamen and lateral ventricular volume  
858 mixed models but was retained by the hippocampal and thalamic models (See FIG 5 and **Tables**  
859 **5, 6**). This outcome in the early-stage cohorts assessed in the present work is consistent Braak et  
860 al. and Aggelton et al findings.

861 Of note, at the time of this writing, a PubMed search (e.g., ((Alzheimer's) in Abstract)  
862 and ((hippocampal volume) in Abstract) and ((mixed model) in Abstract)) returned several  
863 studies utilizing mixed models in Alzheimer's disease research. However, none conducted  
864 univariate mixed models using volume of the subcortical structures (thalamus, cerebellum,  
865 lateral ventricles, putamen) employed in the current work as the dependent variables. Some  
866 studies did include hippocampal volumetry but it seems only one longitudinal study (76) used  
867 hippocampal volume as the response variable and also provided a normalized mixed model

868 estimate (fixed effect coefficient) for the annual effect of time on hippocampal volume. The  
869 latter referenced study focused on MCI and used a metric of normalized volume in mm<sup>3</sup>. When  
870 the mm<sup>3</sup> estimate was converted to percentage of total intracranial volume (ICV, the volume  
871 measure used in the current work) the mixed model coefficient for time (as the solitary predictor  
872 or included with other predictors, such as age) was in a range similar to the current work (-.01 in  
873 our model; -.02 to -.03 in the Huijbers et al <sup>(26)</sup> study).

874 In summary, thalamic volume linear regression explanatory estimates made the greatest  
875 contribution to variation in hippocampal, cerebellar, putamen and lateral ventricular volume.  
876 Mixed models determined the passage of a single year increased lateral ventricular volume,  
877 reduced hippocampal, cerebellar and thalamic volume, but had a negligible effect on putamen  
878 volume. Baseline age had a negative effect on hippocampal and thalamic volume, no effect on  
879 cerebellar or putamen volume and a positive effect on lateral ventricular volume. Moreover, the  
880 group (proxy for AD or potential pathology in MCI) variable's contribution to significant  
881 volume variation was confined to hippocampal volume in linear regression. But in mixed  
882 longitudinal models the group variable significantly contributed to both the hippocampal and  
883 thalamic volume variation. This is one indication that linear models were not as effective as  
884 linear mixed models discriminating early AD pathology in the thalamus. Repeated measure  
885 models generally have more statistical power <sup>(22)</sup>. It is assumed this enabled the mixed model to  
886 detect early AD pathology not just in the hippocampus but in the thalamus as well.

887 Thalamic volume, the pivotal linear regression imaging-derived predictor in the present  
888 work, may, speculatively, along with specific thalamic nuclei<sup>(11)</sup> metrics, provide centralized  
889 insight to AD intervention effects on brain structures with dense thalamic interconnections.

890 There is a growing tide of evidence, linking fasting (such as intermittent fasting) <sup>(78-83)</sup> and  
891 exercise interventions to augmented neurogenesis <sup>(84-88)</sup> - neurogenesis is the antithesis of the  
892 volume reduction correlate neurodegeneration. Supervised exercise and intermittent fasting offer  
893 immediate, substantiated therapeutic and potentially prophylactic benefits for AD <sup>(84-88)</sup>. In the  
894 near future, induced pluripotent stem cell (iPSC) technology <sup>(89-91)</sup> will likely be at the forefront  
895 of AD and other pathology clinical interventions. For a mini up to date review of exercise,  
896 intermittent fasting, iPSC technology and other research relevant to treatment of AD see  
897 Mitigating Neurodegeneration in *Supplementary Information III*. Where neuroimaging data is  
898 available, the primacy of the thalamus as a predictor in the current work supports thalamic  
899 metrics, volume validated here, to aid in intervention assessments.

900 Undoubtedly, the understanding of AD will be advanced by research incorporating  
901 intermittent fasting, exercise and eventually iPSC technology interventions. Imaging will  
902 continue to play a vital role, non-invasively revealing the effects of such interventions. Finally,  
903 mixed models offer standard regression quantification of intervention effects over time. Broader  
904 adoption of mixed models would promote much improved method consistency across  
905 longitudinal study analyses.

### 906 *Limitations*

907 Relatively small sample size ( $N=45$  in linear models;  $N$  of 33-36 in mixed models) and group  
908 size (minimum  $n = 10$  AD in the thalamic mixed model) raise understandable concern about  
909 reproducibility and generalization. In general, an  $N \geq 30$ , according to the central limit theorem,  
910 approximates the population mean and variance. A minimum of  $N \geq 25$  has recently been  
911 estimated for regression models <sup>(92)</sup>. With regard to group  $n$ , a publishing minimum requirement



912 of  $n = 5$  has been stipulated <sup>(93)</sup>. As specified above, this work complied with these  $N$  and group  $n$   
913 minimums, suggesting plausible sample to population model inference. It must also be cautioned  
914 that results could have been impacted by selection bias: data was not randomly selected but  
915 filtered by age, scan resolution and interpreted scan quality. In addition, gender imbalance  
916 (notable in the AD cohort comprised of 27 females and just 3 males) was an unintended  
917 consequence of the data filtering. The filtering may have inadvertently selected individuals with  
918 less genetic-based volume differences, which in turn would diminish a distinguishing gender  
919 variable effect. Finally, evidence of thalamic pathology in early AD is localized largely to the  
920 anterior thalamic nuclei. Consequently, use of only whole thalamic volume likely diminished  
921 thalamic volume coefficient/effect size. Nevertheless, evidence of detectable whole thalamic  
922 volume alteration in AD and in normal ageing has been reported elsewhere (4, [12](#), [67](#)). Most clinical  
923 imaging assessments use whole structure volumes. For these reasons, whole thalamic volume  
924 was used in the current work.

## 925 *Conclusion*

926 Volume, particularly hippocampal volume, is a widely researched metric in AD. Status of other  
927 structures in AD, such as the cerebellum, putamen, lateral ventricles and thalamus, have  
928 collectively undergone less scrutiny. Current work linear regression analyses underlined the  
929 utility of thalamic volume as a virtual centralized index of hippocampal, putamen, cerebellar and  
930 lateral ventricular volume. This is in agreement with but extends introduction literature findings  
931 by further validating the seemingly pervasive influence of the thalamus. Thalamic volume lent  
932 unequalled single-source insight to volume in the other structures and is well supported in the  
933 current work as an explanatory variable of high potential, particularly where the target structure is

934 densely interconnected with the thalamus. In addition, mixed longitudinal models discriminated  
935 and quantified evidence of early AD pathology not just in the hippocampus but also in the  
936 thalamus. This too is congruent with introduction literature findings reporting early AD stage  
937 pathology in these two structures, and supports including thalamic in addition to hippocampal  
938 volume in early-stage AD assessments. The current study findings justify additional similar  
939 research using larger samples. The next phase of this research, with similar but broadened scope,  
940 will include assessment of volume and connectivity relationships among particular thalamic  
941 nuclei (e.g., anterior thalamic nuclei) and other structures, larger samples and a cross-validated  
942 approach.

943 *Disclosure statement*

944 The authors stipulate there were no financial or other relevant influential interests potentially  
945 biasing research. This research did not receive funding from any specific non-profit or  
946 commercial agency.

947 *Conflict of interest*

948 The authors stipulate there was no conflict of interest.

949 *Author Contributions*

950 Verification of CSL<sup>†</sup>'s analyses conducted by MH. Overall proofing and edit suggestions  
951 conducted by WDS and JFD. First authorship = <sup>†</sup>.

952 *Data availability statement*

953 Data used is available directly from ADNI's data access repository ([adni.loni.usc.edu/data-](http://adni.loni.usc.edu/data-samples/access-data/)  
954 [samples/access-data/](http://adni.loni.usc.edu/data-samples/access-data/)). The specific sample used can also available from GitHub  
955 ([https://github.com/csl4r/Subcort\\_Volume](https://github.com/csl4r/Subcort_Volume)) and this website (supporting information Datasets).  
956 The R code can be obtained from the first author ([cslfalcon@gmail.com](mailto:cslfalcon@gmail.com)) anytime.

#### 957 *Abbreviations*

958 ADNI = Alzheimer's Disease Neuroimaging Initiative; AD = Alzheimer's disease; CN =  
959 controls; MCI = mild cognitive impairment; BTB = MRI T1 same-subject scans taken in back-to  
960 -back; CDR = clinical dementia rating; MMSE = mini mental state exam; MPRAGE T1 =  
961 Magnetization Prepared Rapid Acquisition Gradient EchoT1 weighted image; NRMSE =  
962 normalized root mean squared error; V0<sub>A</sub> and V0<sub>B</sub> = baseline BTB same-subject scan pairs;  
963 V12<sub>A</sub> and V12<sub>B</sub> = 12-month BTB same-subject scan pairs.

964

965

#### References

966

- 967 1. Jack CR, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, et al. Antemortem MRI findings  
968 correlate with hippocampal neuropathology in typical aging and dementia. *Neurology*. 2002;58(5):750-7.
- 969 2. Jack CR, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy  
970 correlate with change in clinical status in aging and AD. *Neurology*. 2000;55(4):484-9.
- 971 3. DeLeon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. EARLY MARKER FOR ALZHEIMERS-  
972 DISEASE - THE ATROPHIC HIPPOCAMPUS. *Lancet*. 1989;2(8664):672-3.
- 973 4. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, et al. One-Year  
974 Brain Atrophy Evident in Healthy Aging. *Journal of Neuroscience*. 2009;29(48):15223-31.
- 975 5. Jack CR, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-  
976 based hippocampal volume in mild cognitive impairment. *Neurology*. 1999;52(7):1397-403.
- 977 6. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, et al. MRI of hippocampal  
978 volume loss in early Alzheimers disease in relation to ApoE genotype and biomarkers. *Brain*.  
979 2009;132:1067-77.
- 980 7. Bobinski M, De Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, et al. The histological  
981 validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's  
982 disease. *Neuroscience*. 2000;95(3):721-5.

- 983 8. Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L, et al. Correlates of hippocampal  
984 neuron number in Alzheimer's disease and ischemic vascular dementia. *Annals of Neurology*.  
985 2005;57(6):896-903.
- 986 9. Craig LA, Hong NS, McDonald RJ. Revisiting the cholinergic hypothesis in the development of  
987 Alzheimer's disease. *Neuroscience & Biobehavioral Reviews*; 2011.
- 988 10. Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, et al. Amnestic syndrome of  
989 the medial temporal type identifies prodromal AD - A longitudinal study. *Neurology*. 2007;69(19):1859-  
990 67.
- 991 11. Aggleton JP, Pralus A, Nelson AJD, Hornberger M. Thalamic pathology and memory loss in early  
992 Alzheimer's disease: moving the focus from the medial temporal lobe to Papez circuit. *Brain*.  
993 2016;139:1877-90.
- 994 12. Coupe P, Manjon JV, Lanuza E, Catheline G. Lifespan Changes of the Human Brain In Alzheimer's  
995 Disease. *Scientific Reports*. 2019;9.
- 996 13. Braak H, Braak E. NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES. *Acta*  
997 *Neuropathologica*. 1991;82(4):239-59.
- 998 14. Braak H, Braak E. ALZHEIMERS-DISEASE AFFECTS LIMBIC NUCLEI OF THE THALAMUS. *Acta*  
999 *Neuropathologica*. 1991;81(3):261-8.
- 1000 15. Pedro T, Weiler M, Yasuda CL, D'Abreu A, Damasceno BP, Cendes F, et al. Volumetric Brain  
1001 Changes in Thalamus, Corpus Callosum and Medial Temporal Structures: Mild Alzheimer's Disease  
1002 Compared with Amnestic Mild Cognitive Impairment. *Dementia and Geriatric Cognitive Disorders*.  
1003 2012;34(3-4):149-55.
- 1004 16. Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, et al. Selective changes of resting-state  
1005 networks in individuals at risk for Alzheimer's disease. *Proceedings of the National Academy of Sciences*  
1006 *of the United States of America*. 2007;104(47):18760-5.
- 1007 17. de Jong LW, van der Hiele K, Veer IM, Houwing JJ, Westendorp RGJ, Bollen E, et al. Strongly  
1008 reduced volumes of putamen and thalamus in Alzheimers disease: an MRI study. *Brain*. 2008;131:3277-  
1009 85.
- 1010 18. de Oliveira MS, Balthazar ML, D'Abreu A, Yasuda CL, Damasceno BP, Cendes F, et al. MR imaging  
1011 texture analysis of the corpus callosum and thalamus in amnestic mild cognitive impairment and mild  
1012 Alzheimer disease. *AJNR Am J Neuroradiol*. 2011;32(1):60-6.
- 1013 19. Zarei M, Patenaude B, Damoiseaux J, Morgese C, Smith S, Matthews PM, et al. Combining shape  
1014 and connectivity analysis: An MRI study of thalamic degeneration in Alzheimer's disease. *Neuroimage*.  
1015 2010;49(1):1-8.
- 1016 20. Fama R, Sullivan EV. Thalamic structures and associated cognitive functions: Relations with age  
1017 and aging. *Neuroscience and Biobehavioral Reviews*. 2015;54:29-37.
- 1018 21. Apostolova LG, Green AE, Babakchanian S, Hwang KS, Chou YY, Toga AW, et al. Hippocampal  
1019 atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer  
1020 Disease. *Alzheimer Dis Assoc Disord*. 2012;26(1):17-27.
- 1021 22. Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O'Brien JT. Atrophy of the putamen in  
1022 dementia Lewy bodies but not Alzheimer's disease - An MRI study. *Neurology*. 2003;61(9):1191-5.
- 1023 23. Jacobs HIL, Hopkins DA, Mayrhofer HC, Bruner E, van Leeuwen FW, Raaijmakers W, et al. The  
1024 cerebellum in Alzheimer's disease: evaluating its role in cognitive decline. *Brain*. 2018;141:37-47.
- 1025 24. Hoenig MC, Bischof GN, Seemiller J, Hammes J, Kukolja J, Onur OA, et al. Networks of tau  
1026 distribution in Alzheimer's disease. *Brain*. 2018;141:568-81.
- 1027 25. Guo CC, Tan R, Hodges JR, Hu X, Sami S, Hornberger M. Network-selective vulnerability of the  
1028 human cerebellum to Alzheimer's disease and frontotemporal dementia. *Brain*. 2016;139(Pt 5):1527-38.

- 1029 26. Thomann PA, Schlaefer C, Seidl U, Dos Santos V, Essig M, Schroeder J. The cerebellum in mild  
1030 cognitive impairment and Alzheimer's disease - A structural MRI study. *Journal of Psychiatric Research*.  
1031 2008;42(14):1198-202.
- 1032 27. Tabatabaei-Jafari H, Walsh E, Shaw ME, Cherbuin N, (ADNI) AsDNI. The cerebellum shrinks faster  
1033 than normal ageing in Alzheimer's disease but not in mild cognitive impairment. *Hum Brain Mapp*.  
1034 2017;38(6):3141-50.
- 1035 28. Aggleton JP, O'Mara SM, Vann SD, Wright NF, Tsanov M, Erichsen JT. Hippocampal-anterior  
1036 thalamic pathways for memory: uncovering a network of direct and indirect actions. *European Journal*  
1037 *of Neuroscience*. 2010;31(12):2292-307.
- 1038 29. Ahmet I, Wan RQ, Mattson MP, Lakatta EG, Talan M. Cardioprotection by intermittent fasting in  
1039 rats. *Circulation*. 2005;112(20):3115-21.
- 1040 30. Aumann TD, Rawson JA, Finkelstein DI, Horne MK. PROJECTIONS FROM THE LATERAL AND  
1041 INTERPOSED CEREBELLAR NUCLEI TO THE THALAMUS OF THE RAT - A LIGHT AND ELECTRON-  
1042 MICROSCOPIC STUDY USING SINGLE AND DOUBLE ANTEROGRADE LABELING. *Journal of Comparative*  
1043 *Neurology*. 1994;349(2):165-81.
- 1044 31. Bentivoglio M, Kuypers H. DIVERGENT AXON COLLATERALS FROM RAT CEREBELLAR NUCLEI TO  
1045 DIENCEPHALON, MESENCEPHALON, MEDULLA-OBLONGATA AND CERVICAL CORD - A FLUORESCENT  
1046 DOUBLE RETROGRADE LABELING STUDY. *Experimental Brain Research*. 1982;46(3):339-56.
- 1047 32. Teune TM, van der Burg J, van der Moer J, Voogd J, Ruigrok TJH. Topography of cerebellar  
1048 nuclear projections to the brain stem in the rat. *Cerebellar Modules: Molecules, Morphology, and*  
1049 *Function*. 2000;124:141-72.
- 1050 33. Grodd W, Kumar VJ, Schuez A, Lindig T, Scheffler K. The anterior and medial thalamic nuclei and  
1051 the human limbic system: tracing the structural connectivity using diffusion-weighted imaging. *Scientific*  
1052 *Reports*. 2020;10(1).
- 1053 34. Hwang K, Bertolero MA, Liu WB, D'Esposito M. The Human Thalamus Is an Integrative Hub for  
1054 Functional Brain Networks. *J Neurosci*. 2017;37(23):5594-607.
- 1055 35. Baron JC, Levasseur M, Mazoyer B, Legaultdemare F, Mauguiere F, Pappata S, et al.  
1056 THALAMOCORTICAL DIASCHISIS - POSITRON EMISSION TOMOGRAPHY IN HUMANS. *Journal of*  
1057 *Neurology Neurosurgery and Psychiatry*. 1992;55(10):935-42.
- 1058 36. Carrera E, Tononi G. Diaschisis: past, present, future. *Brain*. 2014;137:2408-22.
- 1059 37. de Jong LW, van der Hiele K, Veer IM, Houwing JJ, Westendorp RGJ, Bollen ELEM, et al. Strongly  
1060 reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study. *Brain (London,*  
1061 *England : 1878)*. 2008;131(12):3277-85.
- 1062 38. Aggleton JP, Desimone R, Mishkin M. THE ORIGIN, COURSE, AND TERMINATION OF THE  
1063 HIPPOCAMPOTHALAMIC PROJECTIONS IN THE MACAQUE. *Journal of Comparative Neurology*.  
1064 1986;243(3):409-21.
- 1065 39. Amaral DG, Cowan WM. SUB-CORTICAL AFFERENTS TO THE HIPPOCAMPAL-FORMATION IN THE  
1066 MONKEY. *Journal of Comparative Neurology*. 1980;189(4):573-91.
- 1067 40. Vogt BA, Pandya DN, Rosene DL. CINGULATE CORTEX OF THE RHESUS-MONKEY .1.  
1068 CYTOARCHITECTURE AND THALAMIC AFFERENTS. *Journal of Comparative Neurology*. 1987;262(2):256-  
1069 70.
- 1070 41. Manjon JV, Coupe P. volBrain: An Online MRI Brain Volumetry System. *Frontiers in*  
1071 *Neuroinformatics*. 2016;10.
- 1072 42. Coupe P, Manjon JV, Fonov V, Pruessner J, Robles M, Collins DL. Patch-based segmentation  
1073 using expert priors: Application to hippocampus and ventricle segmentation. *Neuroimage*.  
1074 2011;54(2):940-54.

- 1075 43. Bakdash JZ, Marusich LR. Repeated Measures Correlation (vol 8, 456, 2017). *Frontiers in*  
1076 *Psychology*. 2019;10.
- 1077 44. Green P, MacLeod CJ. SIMR: an R package for power analysis of generalized linear mixed models  
1078 by simulation. *Methods in Ecology and Evolution*. 2016;7(4):493-8.
- 1079 45. ADNI. Alzheimer's Disease Neuroimaging Initiative. April 3, 2020 at 8:14:42 p.m. EDT.
- 1080 46. Burns A. Mini-Mental State: A practical method for grading the cognitive state of patients for the  
1081 clinician. M. Folstein, S. Folstein and P. McHugh, *Journal of Psychiatric Research* (1975) 12, 189-198.  
1082 Introduction. *International Journal of Geriatric Psychiatry*. 1998;13(5):285-.
- 1083 47. Morris JC. THE CLINICAL DEMENTIA RATING (CDR) - CURRENT VERSION AND SCORING RULES.  
1084 *Neurology*. 1993;43(11):2412-4.
- 1085 48. Morris JC. Early-stage and preclinical Alzheimer disease. *Alzheimer Disease & Associated*  
1086 *Disorders*. 2005;19(3):163-5.
- 1087 49. Jack CR, Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's  
1088 Disease Neuroimaging Initiative (ADNI): MRI methods. *Journal of Magnetic Resonance Imaging*.  
1089 2008;27(4):685-91.
- 1090 50. Newman TB, Browner WS. IN DEFENSE OF STANDARDIZED REGRESSION-COEFFICIENTS.  
1091 *Epidemiology*. 1991;2(5):383-6.
- 1092 51. Bates D, Machler M, Bolker BM, Walker SC. Fitting Linear Mixed-Effects Models Using lme4.  
1093 *Journal of Statistical Software*. 2015;67(1):1-48.
- 1094 52. Cohen J, Cohen P, West SG, Aiken LS. *Applied Multiple Regression Correlation Analysis for the*  
1095 *Behavioral Sciences*. 3rd ed. ed. New Jersey: Lawrence Erlbaum Associates, Inc.; 2003.
- 1096 53. Field AP. *Discovering statistics using R*. Miles J, & Field, Z., editor. London: Sage; 2012.
- 1097 54. Barton K. MuMIn: Multi-Model Inference. *Comprehensive R Archive Network*. 2020.
- 1098 55. Bolker BM, Brooks ME, Clark CJ, Geange SW, Poulsen JR, Stevens MHH, et al. Generalized linear  
1099 mixed models: a practical guide for ecology and evolution. *Trends in Ecology & Evolution*.  
1100 2009;24(3):127-35.
- 1101 56. Westfall J. Five different "Cohen's d" statistics for within-subject designs | *Cookie Scientist* 2021  
1102 [updated December 26, 2021 at 6:52:19 p.m. EST. Available from:  
1103 [http://jakewestfall.org/blog/index.php/2016/03/25/five-different-cohens-d-statistics-for-within-subject-](http://jakewestfall.org/blog/index.php/2016/03/25/five-different-cohens-d-statistics-for-within-subject-designs/)  
1104 [designs/](http://jakewestfall.org/blog/index.php/2016/03/25/five-different-cohens-d-statistics-for-within-subject-designs/).
- 1105 57. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox  
1106 regression. *American Journal of Epidemiology*. 2007;165(6):710-8.
- 1107 58. Harrell FE, Lee KL, Califf RM, Pryor DB, Rosati RA. REGRESSION MODELING STRATEGIES FOR  
1108 IMPROVED PROGNOSTIC PREDICTION. *Statistics in Medicine*. 1984;3(2):143-52.
- 1109 59. J P, D B, S D, D S, Team RC. *Linear and Nonlinear Mixed Effects Models*. 2021.
- 1110 60. Team RC. R: A language and  
1111 environment for statistical computing. R  
1112 Foundation for Statistical Computing,  
1113 Vienna, Austria. URL  
1114 <https://www.R-project.org/2018>.
- 1115 61. Kalin AM, Park MTM, Chakravarty MM, Lerch JP, Michels L, Schroeder C, et al. Subcortical Shape  
1116 Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients. *Frontiers in*  
1117 *Aging Neuroscience*. 2017;9.

- 1118 62. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al.  
1119 Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects. *Annals*  
1120 *of Neurology*. 2009;65(4):403-13.
- 1121 63. Pena EA, Slate EH. Global validation of linear model assumptions. *Journal of the American*  
1122 *Statistical Association*. 2006;101(473):341-54.
- 1123 64. Long JA. jtools: Analysis and Presentation of Social Scientific Data. *Comprehensive R Archive*  
1124 *Network*. 2021.
- 1125 65. J N. *The Human Brain; An introduction to functional anatomy*. Sixth edition ed: Mosby, Elsevier;  
1126 2009. 717 p.
- 1127 66. Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, et al. A meta-analysis of  
1128 hippocampal atrophy rates in Alzheimer's disease. *Neurobiology of Aging*. 2009;30(11):1711-23.
- 1129 67. Fjell AM, Westlye LT, Grydeland H, Amlien I, Espeseth T, Reinvang I, et al. Critical ages in the life  
1130 course of the adult brain: nonlinear subcortical aging. *Neurobiology of Aging*. 2013;34(10):2239-47.
- 1131 68. Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, Williamson A, et al. Regional brain  
1132 changes in aging healthy adults: General trends, individual differences and modifiers. *Cerebral Cortex*.  
1133 2005;15(11):1676-89.
- 1134 69. Walhovd KB, Westlye LT, Amlien I, Espeseth T, Reinvang I, Raz N, et al. Consistent  
1135 neuroanatomical age-related volume differences across multiple samples. *Neurobiology of Aging*.  
1136 2011;32(5):916-32.
- 1137 70. Lin CY, Chen CH, Tom SE, Kuo SH, *Alzheimers Dis Neuroimaging I. Cerebellar Volume Is*  
1138 *Associated with Cognitive Decline in Mild Cognitive Impairment: Results from ADNI*. *Cerebellum*.  
1139 2020;19(2):217-25.
- 1140 71. Thomann PA, Schlafer C, Seidl U, Dos Santos V, Essig M, Schroder J. The cerebellum in mild  
1141 cognitive impairment and Alzheimer's disease - A structural MRI study. *Journal of Psychiatric Research*.  
1142 2008;42(14):1198-202.
- 1143 72. van den Heuvel MP, Sporns O. Rich-club organization of the human connectome. *J Neurosci*.  
1144 2011;31(44):15775-86.
- 1145 73. Yan T, Wang W, Yang L, Chen K, Chen R, Han Y. Rich club disturbances of the human connectome  
1146 from subjective cognitive decline to Alzheimer's disease. *Theranostics*. 2018;8(12):3237-55.
- 1147 74. McDonald CR, McEvoy LK, Gharapetian L, Fennema-Notestine C, Hagler DJ, Jr., Holland D, et al.  
1148 Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. *Neurology*.  
1149 2009;73(6):457-65.
- 1150 75. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*.  
1151 1991;82(4):239-59.
- 1152 76. Huijbers W, Mormino EC, Schultz AP, Wigman S, Ward AM, Larvie M, et al. Amyloid-beta  
1153 deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and  
1154 clinical progression. *Brain*. 2015;138:1023-35.
- 1155 77. Lu N, Han Y, Chen T, Gunzler DD, Xia Y, Lin JY, et al. Power analysis for cross-sectional and  
1156 longitudinal study designs. *Shanghai Arch Psychiatry*. 2013;25(4):259-62.
- 1157 78. Chaix A, Zarrinpar A, Miu P, Panda S. Time-Restricted Feeding Is a Preventative and Therapeutic  
1158 Intervention against Diverse Nutritional Challenges. *Cell Metabolism*. 2014;20(6):991-1005.
- 1159 79. de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease (vol 381,  
1160 pg 2541, 2019). *New England Journal of Medicine*. 2020;382(3):298-.
- 1161 80. Hatori M, Vollmers C, Zarrinpar A, DiTacchio L, Bushong EA, Gill S, et al. Time-Restricted Feeding  
1162 without Reducing Caloric Intake Prevents Metabolic Diseases in Mice Fed a High-Fat Diet. *Cell*  
1163 *Metabolism*. 2012;15(6):848-60.

- 1164 81. Imai S-i, Guarente L. It takes two to tango: NAD(+) and sirtuins in aging/longevity control. *Npj*  
1165 *Aging and Mechanisms of Disease*. 2016;2.
- 1166 82. Lee HC. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. *Annual*  
1167 *Review of Pharmacology and Toxicology*. 2001;41:317-45.
- 1168 83. Lee HC. Cyclic ADP-ribose and NAADP: fraternal twin messengers for calcium signaling. *Science*  
1169 *China-Life Sciences*. 2011;54(8):699-711.
- 1170 84. Kronenberg G, Bick-Sander A, Bunk E, Wolf C, Ehninger D, Kempermann G. Physical exercise  
1171 prevents age-related decline in precursor cell activity in the mouse dentate gyrus. *Neurobiol Aging*.  
1172 2006;27(10):1505-13.
- 1173 85. Marques-Aleixo I, Santos-Alves E, Moreira PI, Oliveira PJ, Magalhaes J, Ascensao A. EXERCISE-  
1174 INDUCED PROTECTION AGAINST AGING AND NEURODEGENERATIVE DISEASES: ROLE OF REDOX- AND  
1175 MITOCHONDRIAL-BASED ALTERATIONS. *Diet and Exercise in Cognitive Function and Neurological*  
1176 *Diseases*. 2015:309-21.
- 1177 86. Steiner JL, Murphy EA, McClellan JL, Carmichael MD, Davis JM. Exercise training increases  
1178 mitochondrial biogenesis in the brain. *Journal of Applied Physiology*. 2011;111(4):1066-71.
- 1179 87. Vina J, Borrás C, Sanchis-Gomar F, Martínez-Bello VE, Ollaso-González G, Gambini J, et al.  
1180 Pharmacological Properties of Physical Exercise in the Elderly. *Current Pharmaceutical Design*.  
1181 2014;20(18):3019-29.
- 1182 88. Zhao N, Xia J, Xu B. Physical exercise may exert its therapeutic influence on Alzheimer's disease  
1183 through the reversal of mitochondrial dysfunction via SIRT1-FOXO1/3-PINK1-Parkin-mediated  
1184 mitophagy. *J Sport Health Sci*. 2021;10(1):1-3.
- 1185 89. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent  
1186 stem cells from adult human fibroblasts by defined factors. *Cell*. 2007;131(5):861-72.
- 1187 90. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult  
1188 fibroblast cultures by defined factors. *Cell*. 2006;126(4):663-76.
- 1189 91. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced  
1190 pluripotent stem cell lines derived from human somatic cells. *Science*. 2007;318(5858):1917-20.
- 1191 92. Jenkins DG, Quintana-Ascencio PF. A solution to minimum sample size for regressions. *Plos One*.  
1192 2020;15(2).
- 1193 93. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA, et al. Experimental  
1194 design and analysis and their reporting: new guidance for publication in *BJP*. *British Journal of*  
1195 *Pharmacology*. 2015;172(14):3461-71.

1196